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IMMUNOLOGY OF LIVER TRANSPLANTATION 
Mechanisms of graft acceptance 
Over a period of 33 years, it has become 
possible to successfully transplant individual 
intra-abdominal viscera or combinations of these 
organs. The consequences have been, first, new 
information about the metabolic interrelations 
that the visceral organs have in disease or 
health; second, the addition of several 
procedures to the treatment armamentarium of 
gastrointestinal diseases; and third, a more 
profound understanding of the means by which 
all whole organ grafts are "accepted". This last 
achievement has been the most fundamental and 
occurred in stages with long periods in between. 
Clinical transplantation began as an 
empirical discipline. Although successes were 
achieved with increasing frequency, it was not 
understood how allografts were able, with the 
aid of immunosuppression, to weather the initial 
attack by the recipient immune system, and later 
to provide increasingly stable function for the 
host. Study of the gastrointestinal organs and 
their recipients have provided unique inSights 
into these processes. 1-5 In 1969, when the liver 
1 Stanl TE, Demetris AJ, Murase N, Ildstad S, 
Ricordi C, Trucco M: Cell migration, chimerism, 
and graft acceptance. Lancet 339:1579-1582, 1992. 
2 Stanl TE, Demetris AJ, Trucco M, et al. Systemic 
chimerism in human female recipients of male 
livers. Lancet 340:876-877 ,1992. 
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became the first transplanted organ to be 
recognized as having a composite (chimeric) 
structure, it was noted that the Kuppfer cells and 
other tissue leukocytes became predominantly 
recipient phenotype within 100 days after 
transplantation while the hepatocytes 
permanently retained their donor specificity 
(figure 1). This transformation was assumed to 
be unique to the hepatic allograft. 
However, 22 years later, first in rat models, 
and then in humans, it was realized that the 
same process occurred in all successfully 
transplanted intestines. The epithelium of the 
bowel remained that of the donor, whereas the 
lymphoid, dendritic and other leukocytes of 
reCipient Origin quickly invaded and became the 
dominant cells in the lamina propria, Peyer's 
patches, and mesenteric nodes. Subsequent 
studies of the kidney and thoracic organs made 
it obvious that all whole organ grafts underwent 
3 Stanl TE, Demetris AJ, Trucco M, et al. 
Chimerism after liver transplantation for Type N 
glycogen storage disease and Type I Gaucher's 
Disease. N Engl J Med 328:745-749,1993. 
4 Stanl TE, Demetris AJ, Murase N, Thomson A W, 
Trucco M, Ricordi C: Cell chimerism permitted by 
immunosuppressive drugs is the basis of organ 
transplant acceptance and tolerance. Immunol Today 
14:326-332, 1993. 
5 Stanl TE, Demetris AJ,Trucco M, et al.: Cell 
migration and chimerism after whole organ 
transplantation: The basis of graft acceptance. 
Hepatology 17:1127-1152,1993. 
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similar changes, differing only quantitatively in 
the number of substituted tissue leukocytes 
which ranged from large in the case of the liver 
to small in organs like the kidney and heart. 
What remained to be determined was the 
fate of the leukocytes vacating the grafts. The 
answers were provided by the longest survivors 
in the world after kidney transplantation (30 
years) or after receiving a liver (23 years) who 
came to Pittsburgh in the spring and early 
summer of 1992 to be restudied. 1-5 Biopsies 
were obtained from each of these patients 
bearing someone else's liver or kidney, and also 
from more recently treated recipients of hearts, 
lungs, and intestines. The samples were taken 
from the transplanted organ as well as from the 
patient's own skin, lymph nodes, and other 
tissues. 
Then, after special staining procedures 
(immunostaining or sex identification after 
fluorescence in situ hybridization [FISH]), the 
tissues were examined under the microscope to 
see if the individual cells that made them up had 
come from the organ donor, the recipient's own 
body, or both. Alternatively, the donor and 
recipient contributions to any specimen could be 
separated by polymerase chain reaction ("DNA 
Fingerprinting") techniques. 
The answers that came from these analyses 
and from supporting laboratory experiments in 
animals showed that within minutes after 
restoring the blood supply of any transplant, 
myriads of sessile, but potentially migratory 
leukocytes that are part of the normal structure 
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of all organs, left the graft and migrated allover 
the recipient. In the meanwhile, similar reCipient 
cells took their place in the transplant without 
disturbing the highly specialized donor 
parenchymal cells. The relocated donor and 
reCipient leukocytes learned to live in harmony, 
provided they were given sufficient protection 
during their nesting, by immunosuppressive 
drugs. In this new context, the drugs could be 
viewed as traffic directors, allowing movement 
of the white cells in both directions (to and from 
the graft) but preventing the immune destruction 
that is the normal purpose of this traffic. 
It is not known yet how the two sets of 
white cells - a small population from the 
donated organ and a large one that is in essence 
the entire recipient immune system of the 
patient - reach a "truce". TIlls is so complete in 
some cases that immunosuppression can be 
stopped, particularly after liver transplantation 
but less constantly with other organs. Such a 
stable biologic state can be induced more easily 
by the liver than by other transplanted organs 
because of the liver's higher content of the 
critical missionary leukocytes that apparently 
include pluri-potent stem cells. 
While still incomplete, this much 
information already provides a tool with which 
to shape future strategies. The migratory cells 
can be purified from the bone marrow or spleen 
of a donor and then infused to improve the 
"acceptability" of various organs from that 
specific donor probably including those taken 
from an animal for use in humans as xenografis. 
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The cell migration and mixed chimerism 
phenomena make comprehensible the 
unexpected inability of donor-recipient HLA 
matching to accurately predict the outcome of 
whole organ transplantation; neither the new 
organ nor its new host remain the same as at the 
time of the matching tests. 
Allograft rejection 
Rejection is the most common non-
technical complication after liver 
transplantation. Three major types of rejection 
have been described: hyperacute rejection, acute 
cellular rejection, and chronic rejection. 
Hyperacute rejection 
For many years, the liver was though to be 
resistant to antibody mediated hyperacute 
rejection and immediate graft failure was 
usually attributed to preservation failure or pre-
existing ischemic graft damage rather than 
immunological phenomena. In contrast to renal 
transplantation, there was little evidence that the 
presence of preformed donor specific cytotoxic 
anti-lymphocyte (anti-HLA) antibodies was 
damaging to liver grafts.6 In addition, successful 
kidney transplantation, in spite of a positive 
donor specific crossmatch, has been reported in 
patients who first receive a liver transplant from 
the same donor, but this protective effect of a 
6 Gordon RD, Fung 11, Markus B, et al. Tbe 




prior liver transplant cannot always be relied 
upon.1- 9 
Recent animal studies in rat, primate, and 
pig models, have demonstrated that hyperacute 
rejection of the liver can be produced in animals 
presensitized to a liver donor.lO-12 It is now 
recognized that the presence of preformed 
antibody can result in hyperacute rejection of a 
human liver allograft. The risk is greatest when 
a liver graft is placed in a recipient with an 
incompatible ABO blood type, but hyperacute 
7 Fung J, Griffin M, Duquesnoy R, Shaw B, Starzl 
T. Successful sequential liver-kidney transplantation 
in a patient with prefonned lymphocytotoxic 
antibodies. Transplant Proc 19:767-8, 1987. 
8 Dovoux D, Cberqui D, Shultz K, et aI. Double 
liver-kidney transplantation in the presence of a 
positive T cross match. Presse Med 21:2015-6, 
1992. 
9 Eid A, Moore SB, Wiesner RH, DeGoey SR, 
Nielson A, Krom RA. Evidence the liver does not 
always protect the kidney from hyperacute rejection 
in combined liver-kidney transplantation across a 
positive lympbocyte cross match. Transplantation 
50:331-4, 1990. 
10 Knechtle SJ, Kolbech, Tsuchimoto S, et al. 
Hepatic transplantation into sensitized recipients. 
Demonstration of byperacute rejection. Transplant-
ation 43:8-12, 1987. 
11 Gubematis G, Lauchart W, Jonker M, et al. Signs 
of hyperacute rejection of liver grafts in rhesus 
monkeys after donor-specific presensitization. 
Transplant Proc 19:1082-3, 1987. 
12 Merion RM, Colletti LM. Hyperacute rejection in 
porcine liver transplantation. I. Clinical charac-
teristics, histopathology, and disappearance of 
donor-specific lymphocytotoxic antibody from 
serum. Transplantation 49:861-8, 1990. 
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rejection has also now been described in patients 
receiving ABO compatible grafts. 13-16 The usual 
morphological findings are a massive 
hemorrhagic necrosis evolving within hours or 
days of reperfusion of the graft. Deposits of 
immunoglobulin, the C-3 component of 
complement, properidin and fibrinogen are 
characteristic findings. 17 A necrotizing or 
neutrophilic arteritis is also seen. Because of the 
risk of hyperacute rejection, liver transplantation 
across incompatible ABO blood groups is 
hazardous and is contraindicated except in the 
most urgent circumstances. 
Although the risk of antibody mediated 
hyperacute rejection in patients with preformed 
donor specific anti-HLA cytotoxic antibodies 
who receive ABO compatible graft remains 
13 Demetris Al, Jaffe R, Tzakis A, et al. Antibody-
mediated rejection of human orthotopic liver 
allografts. A study of liver transplantation across 
ABO blood group barriers. Am J Pathol 132:489-
502,1988. 
14 Rego J, Prevost F. Rumeau JL, et al. Hyperacute 
rejection after ABO incompatible orthotopic liver 
transplantation. Transplant Proc 19:4589-90, 1987. 
15 Cienfuegos JA, Pardo F, Hernandez J, Camps J, 
Quiroga J, Pardo J. Hyperacute rejection in liver 
transplantation: morphological and clinical 
characteristics. Transplant Proc 24:141-2, 1992. 
16lmagawa DK, Noguchi K, Iwaki Y, Busuttul RW. 
Hyperacute rejection following ABO-compatible 
orthotopic liver transplantation - a case report. 
Transplantation 54:114-7, 1992. 
17 Gubematis G, Kemnitz J, Bomscheuer A, et al. 
Potential various appearances of hyperacute 
rejection in liver transplantation. Lagenbecks Arch 
Chir 374:20, 1989. 
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acceptably low, there is increasing evidence that 
the presence of preformed antibody increases the 
risk of late graft loss. Demetris et al reported a 
higher incidence of cellular rejection episodes 
and a higher rate of graft loss within 180 days of 
transplantation in recipients with preformed IgG 
lymphocytotoxic antibodies. 18 Although 
hyperacute rejection was not seen in these 
patients, platelet margination in central veins, 
acute cholangiolitis, centrilobular hepatocyte 
swelling similar to that seen in ischemic grafts, 
endothelial activation in arteries with medial 
changes, and recurring episodes of acute cellular 
rejection were commonly found. Peri operative 
administration of prostaglandin El (pGEl) may 
offer a protective advantage when grafting 
across a positive crossmatch. 19 
In a recent comparison of liver recipients 
maintained on an FK506 and prednisone 
protocol, antibody cross-match negative graft 
recipients had significantly better one year 
patient and graft survival rates (86% and 82%) 
than antibody cross-match positive reCipients 
(68% and 56%).20 In addition, cross-match 
18 Demetris Al, Nakamura K, Yagibashi A, et al. A 
clinicopathological study of human liver allograft 
recipients harboring preformed IgG 
lymphocytotoxic antibodies. Hepatology 16:671-81, 
1992. 
19 Talmya S, Iwaki Y, Starzl lE. Liver 
transplantation in positive cytotoxic crossmatch 
cases using FK 506, high dose steroids, and 
prostaglandin El. Transplantation 54:927-9, 1992 
20 Takaya S, Bronsther 0, Iwaki Y, et al. The 
adverse impact on liver transplantation of using 
Orthotopic Liver Transplantation 
positive patients also required more blood 
products during surgery and had poorer initial 
graft function. The refractoriness of 
thrombocytopenic patients to platelet 
transfusions may be aggravated by anti-HLA 
antibodies. 21 
Acute cellular rejection 
Acute cellular rejection may occur at any 
time after transplantation, but is most commonly 
seen clinically in the first 10 days to 2 months 
after transplantation. However, evidence of 
early rejection has been reported in 44% of 
protocol biopsies only 5 days after 
transplantation.22 In those patients with early 
rejection on the day-5 biopsy, 67% ultimately 
required treatment with OKT3 for reversal, and 
recurrent rejection episodes were more common. 
Klintmalm et al observed at least one 
episode of acute cellular rejection in 60.6% of 
104 liver graft recipients treated with a baseline 
regimen of cyclosporine and prednisone. In this 
series, 42.3% of the patients had only one 
rejection episode. Of the 63 first episodes of 
rejection, 60 occurred within 21 days of 
positive cytotoxic crossmatch donors. 
Transplantation 53: 400-6, 1992. 
21 Marino JR, Weber T, Kang YG, Esquivel CO, 
Starzl re, Duquesnoy R. HLA alloimmunization in 
orthotopic liver transplantation. Transplant Proc 
21:789, 1989. 
22 Brunt EM, Peters MG, FIye MW, Hanto DW. 
Day-5 protocol liver allograft biopsies document 
early rejection episodes and are predictive of 
recurrent rejection. Surgery 111 :511-7, 1992. 
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transplantation. Anti-rejection therapy with 
steroids or OKTI was highly effective and only 
two patients eventually lost their grafts to 
rejection. 23 
The intrahepatic bile ducts and vascular 
endothelium, both of which express major 
histocompatibility (MHC) antigens and 
adhesion molecules, are the main targets of the 
immunological response. Liver biopsy remains 
the gold standard for diagnOSiS. Rejection must 
be differentiated from manifestations of vascular 
or biliary tract technical complications, 
preservation injury, opportunistic viral infection, 
drug toxicity, or any combination of the above. 
Typical findings of acute cellular rejection 
include a lymphocytic infiltrate in the portal 
tracts with involvement of the bile ducts and 
endothelium of the portal veins. The central 
veins may also display a venulitis. The hepatic 
lobules are usually uninvolved except in severe 
cases when the mononuclear infiltrate may spill 
over the limiting plate and be associated with 
hepatocyte necrosis. This morphology is quite 
distinct from the piecemeal necrosis 
characteristic of hepatitis. Ominous findings on 
biopsy include paucity of bile ducts, arteritis, 
and hepatocellular ballooning 'with 
hepatocellular dropout. The degree of bile duct 
damage (as opposed to bile duct loss), the 
severity of the lymphocytic infiltrate, and the 
23 Klintmalm GB, Nery JR, Husberg BS, Gonwa 
T A, Tillery GW. Rejection in liver transplantation. 
Hepatology 10:978-85, 1989. 
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mere presence of hepatocellular necrosis are not 
reliable predictors of outcome. 24 
Considerable effort has been devoted to 
finding markers of rejection that could be 
obtained by non-invasive means. Soluble 
interleukin-2 receptors (IL-2R) have been 
measured as a marker of lymphocyte activation 
in serum and bile. Both serum and bile levels of 
IL-2R are elevated 24 hours prior to the 
detection of acute rejection by other means and 
levels in bile are more specific and more 
sensitive than serum levels.25 Hyaluronic acid 
(HA) and factor VIII related antigen (VIIIRAg), 
which detect endothelial damage, have also been 
measured. Elevated HA levels were found in 
patients with acute rejection and were highest in 
patients who went on to develop chronic 
rejection. VIIIRAg was elevated in all recipients 
and did not discriminate between rejection and 
other complications.26 
The usual treatment of mild to moderate 
rejection is corticosteroids. More severe 
rejection or steroid-resistant rejection is treated 
24 Snover DC, Freese DK, Sharp l:ll.." et al. An 
analysis of the use of biopsy in determining outcome 
of rejection. Am J Surg Patholll:1-1O, 1987. 
25 Adams DH, Wang L, Hubscher SG, Elias E, 
Neuberger lM. Soluble interleukin-2 receptors in 
serum and bile of liver transplant recipients. Lancet 
1:469-71,1989. 
26 Adams DH, Wang L, Hubscher SG, Neuberger 
lM. Hepatic endothelial cells. Targets in liver 




with monoclonal or polyclonal anti-lymphocyte 
antibody, as discussed below. In a recent study, 
eight patients with characteristic histological 
findings of rejection, including bile duct damage 
and endothelialitis, were observed to recover 
from rejection without additional 
immunosuppression.27 This suggests that acute 
rejection is part of the adaptive process between 
host and graft that does not necessarily lead to 
permanent graft damage or graft loss. However, 
since it is difficult to tell in which patients 
rejection will resolve spontaneously, treatment 
is usually advisable if characteristic histological 
findings are present. 
Acute rejection occurring more than six 
months after transplantation is less common, but 
usually responds well to steroid therapy. Many 
late rejections are associated with low levels of 
immunosuppression and compliance problems, 
but biliary tract complications should also be 
evaluated. The incidence of progression to 
chronic rejection is similar with early (7.0%) or 
late rejection (7.7%).28 
Angiographic abnormalities may be found 
in patients with acute rejection, including 
varying degrees of intrahepatic arterial 
narrowing, stretching of the intrahepatic arterial 
27 Dousset B, Hubscber SG, Padbury RT, et al. 
Acute liver allograft rejection - is treatment always 
necessary? Transplantation 55:529-34, 1993. 
28 Mor E, Gonwa T A, Husberg BS, Goldstein RM, 
Klintmalm GB. Late-onset rejection in orthotopic 
liver transplantation. - associated risk factors and 
outcome. Transplantation 54:821-4, 1992. 
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tree, poor peripheral arterial filling, and a 
decrease in the number of intrahepatic arteries. 29 
The increased resistance to flow in the rejecting 
graft may result in changes in the Doppler flow 
signal and be mistaken for hepatic arterial 
thrombosis. 
Chronic rejection 
Chronic allograft rejection develops in 10 
to 15% of liver recipients. Its characteristic 
feature is a chronic obliterative arteriopathy 
leading to progressive loss of small bile ducts. 
Small portal arterioles less than 35 microns and 
bile ducts which should accompany arteries 
ranging from 35 to 74 microns in diameter are 
missing, with the greatest loss occurring 
amongst the smallest ducts. Histopathological 
evidence of large vessel arteriopathy is often 
absent. 3D 
Other histological findings seen in chronic 
allograft rejection include centrilobular 
cholestasis· and hepatocyte atrophy or 
ballooning, intrasinusoidal foam cells, spotty 
acidophilic necrosis, and peri venular sclerosis. 
All of these changes reflect a progressive 
ischemic injury. 
29 White RM, Zajko AB, Demetris AJ, et al. Liver 
transplant rejection:angiographic findings in 35 
cases. Am I RoentgenoI148:2095-8, 1987. 
3D Oguma S, Belle S, StarzllE, Demetris AI. A 
histometric analysis of chronically rejected human 
liver allografts: insights into the mechanism of bile 
duct loss. Hepatology 9:204-9, 1989. 
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Progressive cholestatic jaundice with 
elevated canalicular enzymes is the usual 
clinical presentation of chronic rejection. The 
diagnosis is established by liver biopsy and 
investigation to rule out other problems 
including viral hepatitis, hepatic artery or portal 
vein thrombosis, biliary obstruction, viral or 
toxic hepatitis, systemic infection, and recurrent 
disease. Chronic rejection is a relentless process 
that generally does not respond to additional 
immunosuppressive therapy. Although the early 
stages of chronic rejection may respond to 
conversion of patients from cyclosporine to 
FK 506, patients with well established chronic 
rejection eventually require retransplantation.31 
Vanishing bile duct syndrome 
An interesting variant of chronic rejection 
is the "vanishing bile duct syndrome" (VBDS) 
characterized by an obliterative cholangitis and 
ductopenia within 3 months oftransplantation.32 
An increased incidence of VBDS has been 
associated with a positive lymphocytotoxic 
crossmatch, ~A mismatch, and CMV 
infection.33, 34 It has been hypothesized that 
31 Demetris AJ, Fung JJ, Todo S, et al. Conversion 
of liver allograft recipients from cyclosporine to FK 
506 immunosuppressive therapy a 
clinicopathologic study of 96 patients. 
Transplantation 53:1056-62, 1992. 
32 Ludwig J, Wiesner RH, Batts KP, Perkins JO, and 
Keom RA. The acute vanishing bile duct syndrome 
(acute irreversible rejection) after orthotopic liver 
transplantation. Hepatology 7:476-83, 1987. 
33 Batts KP, Moore SB, Perkins JO, et al. fnfluenc~ 
of positive lymphocyte corssmatch and HLA 
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CMV infection, which augments expression of 
HLA antigens on bile duct epithelium, 
stimulates the immune response leading to 
destruction of small bile ducts and that 
cytokines produced in response to CMV 
infection may augment immune responses to the 
allograft. A more recent re-analysis by the Mayo 
Clinic group failed to confirm the association 
between HLA typing, CMV serology, or clinical 
CMV infection and VBDS.35 However, the 
King's College group, using a more sensitive 
assay for viral DNA, was able to detect CMV 
DNA in 10 of 12 patients with VBDS, in all 18 
patients studied with clinical CMV infection, 
and in none of 10 patients with neither infection 
nor VBDS.36 
The relationship between CMV replication 
in the liver and VBDS requires further 
investigation. In the meantime, the incidence of 
mismatching on vanishing bile duct syndrome in 
human liver allognlfts. Transplantation 45:376-9, 
1988. 
34 O'Grady JG, Alexander GJ, Sutherland S, 
Donaldson P, et al. Cytomegalovirus infection and 
donor recipient lILA antigens: interdependent co-
factors in pathogenesis of vanishing bile-duct 
syndrome after liver transplantation. Lancet 2:302-5, 
1988. 
35 Paya CV, Wiesner RH, Hermans PE, et al. Lack 
of association between cytomegalovirus infection, 
lILA matching and the vanishing bile duct 
syndrome after liver transplantation. Hepatology 
16:66-70, 1992. 
36 Arnold JC, Portmann BC, O'Grady JG, et al. 
Cytomegalovirus infection persists in the liver graft 




VBDS is declining, possibly as a result of better 
immunosuppression with triple drug regimens or 
FK 506, as well as improved management of 
CMV infection with prophylactic acyclovir and 




Cyclosporine, an II-amino acid cyclic 
peptide, is a highly lipid soluble 
immunosuppressant which is extensively bound 
to plasma proteins. Cyclosporine blocks the 
production of IL-2, an important cytokine 
produced by activated T-Iymphocytes, by 
disrupting calcium dependent activation 
pathways in the T-cell. Cyclosporine is 
metabolized by the liver and excreted in bile 
with only trace amounts excreted unchanged in 
the urine. At least ten metabolites have been 
identified, but are not well characterized. 
Absorption and dosage required to achieve 
adequate therapeutic blood levels are highly 
variable and necessitate careful monitoring of 
each patient. 
37 Pirsch JD, Kalayoglu M, Hafez GR, et al. 
Evidence that the vanishing bile duct syndrome is 
vanishing. Transplantation 49:1015-7, 1990. 
38 Van Hoek B, Weisner RH, Ludwig J, et al. 
Combination immunosuppression with azathioprine 
reduces the incidence of ductopenic rejection and 
vanishing bile duct syndrome after liver 
transplantation. Transplant Proc 23:1403-5,1991. 
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After liver transplantation, the drug is given 
as 3. continuous intravenous infusion at a dose of 
3 to 5 mg/kg per day. Oral therapy at 10 to 
12 mg/kg per day in two divided doses is begun 
as soon as gastrointestinal function permits, and 
is overlapped with intravenous therapy for 
several days until stable trough blood levels are 
obtained. 
Cyc1osporine is nephrotoxiC and acutely 
produces a hyperkalemic renal tubular acidosis. 
Chronic cyc1osporine nephrotOxicity is 
characterized by a progressive interstitial 
fibrosis. To avoid nephrotoxicity in the early 
postoperative period, cyc1osporine may be 
withheld during the first 5 to 7 days after 
transplantation, during which time various 
combinations of azathioprine, prednisone, and 
polyc1onal (ATGAM®, Upjohn) or monoclonal 
(Orthoclone OKT-3®, Ortho Pharmaceuticals) 
antilymphocyte antibody preparations are given. 
Oral cyc1osporine is started when renal function 
has stabilized. Intravenous cyc1osporine can also 
be avoided by giving cyclosporine via 
nasogastric tube, but absorption is highly 
variable early after transplantation and 
dependent upon both bowel function and bile 
production. 
Other common manifestations of 
cyclosporine toxicity include hypertension, 
tremors, hypertrichosis, and gingival 
hyperplasia. Central nervous system 
abnormalities include fever, seizures, 
hallucinations and paranoid delusions, motor 
disorders and quadriplegia, speech disturbances, 
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cortical blindness, delirium and coma. 
Reversible changes in cerebral white matter may 
be seen on CT and magnetic resonance imaging 
studies. An association between CNS toxicity 
and low serum cholesterol has been suggested, 
but hypocholesterolemia is not present in all 
cases.39• 40 Reduction in cyc1osporine dosage 
usually results in improvement. Steroid toxicity, 
hypomagnesemia, low serum ionized calcium, 
and hypernatremia must also be considered in 
patients with suspected immunosuppression-
associated neurotoxicity. 
Cyclosporine elimination is dependent 
upon the hepatic cytochrome P-450 microsomal 
enzyme system. Other drugs which induce or 
inhibit this system will affect cyclosporine 
clearance. Enzyme inducing effects occur over 
several weeks and, when the inducing agent is 
withdrawn, the effect takes a similar time to 
reverse. Enzyme inhibition has a more rapid 
impact, as drug accumulation begins quickly 
and requires an early reduction of cyclosporine 
dosage. 
Corticosteroids 
Corticosteroids (prednisone and 
methylprednisolone) are used routinely as part 
39 de Groen PC, Akasmit AJ, Rakela J, Forbes GS, 
Krom RA. Central nervous system toxicity after 
liver transplantation. The role of cyclosporine and 
cholesterol. N Eng1 J Med 317:861-6, 1987. 
40 Truwit CL, Denaro CP,Lake JR, Demarco T. MR 
imaging of reversible cyclosporine A induced 
neurotoxicity. Am J keuroradio11O:SR1~9I 1991. 
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of the immunosuppression induction and 
maintenance protocols after liver 
transplantation. The 11-oxo group of prednisone 
is reduced in the liver to form the biologically 
active steroid prednisolone. An eqUilibrium 
between prednisone and prednisolone is 
established after oral administration and first 
pass through the liver. Even in patients with 
severe liver disease, interconversion of 
prednisone and prednisolone is not a limiting 
factor.41 
For induction of immunosuppression, adult 
patients typically receive an intravenous bolus 
of one gram methylprednisolone 
intraoperatively, followed by a 5-day taper of 
high dose steroids, usually starting at 200 mg 
per day in four divided doses and reduced daily 
by 40 mg per day until a baseline of 20 mg per 
day is reached. As soon as gastrointestinal 
function permits, the patient is given oral 
prednisone. Pediatric patients ( < 30 kg) receive 
a reduced dosage schedule, usually beginning at 
100 mg on the first day and reduced by 20 mg 
Per day to reach a baseline of 10 mg to 20 mg 
per day. 
Corticosteroids also remain the first-line 
drug of choice for the treatment of mild or 
moderate acute cellular rejection. Typical 
treatment includes a repeat bolus of 
41 Frey BM, Frey FJ. Clinical pbannakokinetics of 




methylprednisolone followed by a repeat of the 
5-day steroid taper. 
Since the introduction of cyclosporine, it 
has been possible to taper steroid maintenance 
levels much more quickly that was possible 
under regimens based on azathioprine. There 
have also been several reported series of 
successful withdrawal of patients from 
prednisone within three to six months after 
transplantation.42, 43 However, patients must be 
carefully monitored for acute rejection if 
withdrawal is attempted, and steroids should be 
promptly reinstituted in those cases in which 
acute rejection occurs. 
Azathioprine 
Azathioprine (Imuran®) is an analog. of 
6-mercaptopurine which, in combination with 
steroids, was the mainstay of clinical 
immunosuppression prior to the introduction of 
cyclosporine. It is a bone marrow suppressant 
and leukopenia is the usual dose limiting effect 
of the drug. Today, it is still used in moderate 
dosage as an adjunctive agent with cyclosporine 
and prednisone in patients unable to tolerate 
42 Margarit C, Martinez V, Inbanez V, Tonno R, 
Infante D, Iglesias H. Maintenance 
immunosuppression without steroids in pediatric 
liver transplantation. Transplant Proc 21:2230-1, 
1989. 
43 Padbury RT, Gunbson BK, Dousset B, et al. 
Steroid withdrawal from long-tenn 
immunosuppression in liver allograft recipients. 
Transplantation 55:789-94, 1993. 
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usual dosages of cyclosporine, or to augment 
immunosuppression in patients with persistent 
or recurrent rejection. 
Anti-lymphocyte antibody preparations 
At the present time ATGAM® (Upjohn), a 
polyclonal antilymphocyte globulin and 
monoclonal Orthoclone OKTI® (monomurab-
CD3, Ortho Pharmaceuticals) are the only 
antibody preparations in widespread use for the 
treatment of severe or steroid resistant acute 
cellular rejection. These agents are also used for 
their cyclosporine sparing effect in the early 
postoperative period. 
OKT3 is an Ig2a murine monoclonal 
antibody which has been shown to be highly 
effective in reversing steroid resistant acute 
cellular rejection.44, 45 It is supplied in 5 cc 
ampoules containing 5 mg of drug. The 5 cc 
dose is administered as an intravenous bolus in 
less than one minute daily for 10 to 14 days. 
OKTI is active against the CD3 molecule in the 
T-cell membrane, a moiety associated with the 
antigen recognition structure and activation of 
signal transduction in T-Iymphocytes. Binding 
results in both a rapid decrease in the number of 
44 Cosimi AB, Cho SI, Delmonico FL, et al. A 
randomized clinical trial comparing OKT3 and 
steroids for treatment of hepatic allograft rejection. 
Transplantation 43:91-5, 1987. 
45 Fung n, Demetris AJ, Porter KA, et al. Use of 
OKT3 with ciclosporine and steroids for reversal of 
acute kidney and liver allograft rejection. Nephron 
46 (suppll):19-33, 1987. 
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circulating CD3 positive cells and a functional 
inactivation of the T-cell receptor. Activated T-
cells release numerous cytokines. Premedication 
with methylprednisolone, acetaminophen, and 
antihistamine helps reduce the side effects of the 
cytokine release syndrome commonly 
experienced by patients during the first few days 
of administration. 
OKTI has also been advocated for 
prophylactic use in the first 7 to 14 days after 
transplantation to reduce the incidence of acute 
rejection and to avoid the nephrotoxic effects of 
cyclosporine. However, recent studies have 
failed to demonstrate any lasting benefit from 
prophylactic use of OKTI. Rather it is best 
reserved for treatment of steroid resistance acute 
cellular rejection or when cyclosporine must be 
withheld for a limited period.46• 47 
Since OKTI is a mouse protein, patients 
may develop anti-murine antibodies as a result 
of its use. Continued immunosuppression with 
steroids, azathioprine, or cyclosporine 
influences the titer, time course, and specificity 
of the anti-murine antibodies formed. 
Retreatment with OKTI is usually ineffective in 
patients with significant titers of anti-murine 
46 McDiarmid SV, Busuttil RW, Levy P, et al. The 
long' term outcome of OKT3 compared with 
cyclosporine after liver transplantation. 
Transplantation 52:91-97, 1991. 
47 Hockerstedt K, Ericzon B-C, Bismuth H, et aI. 
OKT3 prophylaxis in liver transplant patients: a 
European and Australian multicenter, prospective 
controlled trial. Transplant Proc 25:556-7, 1993. 
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antibody and sensitization should be suspected 
in patients with poor clearance of CD3 positive 
cells or low serum levels of OKT3. 
New immunosuppressive agents 
FK506 (PrografSl) 
FK506, a 23-member ring macrolide 
lactone belonging to the same family of 
compounds as eythromycin, "is a potent 
immunosuppressive agent. Although the 
chemical stru"cture and cell receptor of FK506 
are both different than those of cyclosporine, it 
has similar effects on T-cell function, including 
blocking of the antigen induced, calcium 
dependent signal transduction which leads to 
transcription of IL_2.48, 49 Calcineurin, a 
Ca++/calmodulin activated phosphatase, appears 
to be a common target when FK 506 and CsA 
are bound to their respecti ve immunophilins, FK 
S06-binding protein (FKBP) and cyclophillin 
(CyP).50, 51 There is also clinical experience 
48 Kronke M, Leonard WJ, Depper JM, et al. 
Cyclosporine A inhibits T-cell growth factor gene 
expression at the level of mRNA transcription. Proc 
Nat Acad Sci 81:5214-8, 1984. 
49 Kino T, Hatanaka H, Miyata S, et al. FK-506, a 
novel immunosuppressant isolated from 
Streptomyces. II. Immunusuppressant effect of FK-
506 in vitro. J Antibiot 40: 1256-65, 1987. 
50 Liu J, Farmer DJ, Lane WS, Friedman J, 
Weissman I, Schreiber SL. Calcineurin is a common 
target for of cyclophilin-cyclosporine A and FKBP-
FK506 complexes. Cell 66:807-5, 1991. 
51 Lane BC, Miller LN, Kawai M, et al. Evaluation 
of calcineurin's role in the immunosuppressive 
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suggesting that FK 506 is an effective inhibitor 
of humoral mechanisms of rejection. 52 
In extensive clinical trials at the University 
of Pittsburgh and in ,recent multicenter trials in 
the United States, FK506 has been found to be 
compare favorably to cyclosporine for induction 
and maintenance immunosuppression after liver 
transplantation. It has also been used to rescue 
grafts from refractory rejection in patients 
treated initially with cyclosporine.53-57 
FK 506 is not dependent upon bile for its 
absorption, but it is metabolized on first pass 
through the liver. Therefore, blood levels may 
activity of FK 506, related macrolactams, and 
cyclosporine. Transplant Proc 25: 644-6, 1993. 
52 Woodle E, Perdrizet GA, -B~nt EM, et al. FK506: 
inhibition of humoral mechanisms of hepatic 
allograft rejection. Transplantation 54:377-81, 1992. 
53 Starzl TE, Fung JJ, Venkatarammanan R, Todo S, 
Demetris AJ, Jain A. FK 506 for liver, kidney, and 
pancreas transplantation. Lancet 2: 1000, 1989. 
54 Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, 
and thoracic organ transplantation under FK 506. 
Ann Surg 212:295-305, 1990. 
55 Fung JJ, Todo S, Jain A, et al. Conversion from 
cyclosporine to FK 506 in liver allograft recipients 
with cyclosporine related complications. Transplant 
Proc 22:6-12, 1990. 
56 US Multicenter FK506 Liver Study Group. Use of 
Prograf (FK 506) as rescue therapy for refractory 
rejection after liver transplantation. Transplant Proc 
25:679-88, 1993. 
57 Jost U, Winkler M, Ringe B, Rodeck B, 
Pichlmayr R. FK 506 treatment of intractable 
rejection after liver transplantation. Transplant Proc 
25:2666-7, 1993. 
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remain elevated in patients with poor graft 
function and close monitoring of blood or serum 
levels is important. Nephrotoxicity, as with 
cyclosporine, is the most common dose-limiting 
side effect. 58 Gastrointestinal side effects, 
including depression of appetite, nausea, and 
diarrhea, are common early in the course of 
treatment, and may in part be due to an 
antibiotic effect of the drug on the gut flora. 
Hypertension is less common with FK 506 than 
with cyclosporine and, when present, is often 
easier to control. Central nervous system 
toxicity is similar to that seen with cyclosporine. 
However, patients presenting with eNS toxicity 
on either cyclosporine or FK506 will usually 
improve when switched from one drug to the 
other, or if the dosage of the drug being used is 
reduced markedl y. 
RS·61443 (Mycophenolate mofetil) 
RS-61443, the morphomonoethyl ester of 
mycophenolic acid (MP A), is a potent inhibitor 
of inosine monophosphate dehydrogenase. It 
interferes with the replication of DNA by 
inhibition of guanosine nucleotide formation. 
Since lymphocytes are dependent upon de novo 
synthesis of guanine nucleotides and lack the 
salvage pathway found in other rapidly dividing 
cell lines, MPA and RS-61443 have a 
preferential inhibitory effect on lymphocyte 
proliferation. Early clinical trials suggest that 
58 Alessiani A, Cillo U, Fung JJ, et al. Adverse 
effects of FK 506 overdosage after liver 
transplantation. Transplant Proc 25:628-34, 1993. 
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RS-61443 is an effective immunosuppressant 
when used in combination with steroids for 
maintenance therapy and for rescue of rejecting 
liver allografts. 59. 60 Further trials are awaited 
with interest. 
Rapamycin 
Rapamycin is a lipophilic macrolide with a 
chemical structure closely resembling FK506. 
Despite the structural similarity to FK 506, 
raparnycin does not block IL-2 production and 
appears to act later in the lymphocyte activation 
cascade between the Gland S phase of the cell 
cycle.61-63 Thus, rapamycin can act to suppress 
an immune response after T-cell activation and 
can even act as an antagonist to FK 506. 
Rapamycin shows significant promise as an 
59 Klinunalm GB, Ascher NL, Busuttil RW, et al. 
RS-61443 for treaunent-resistant human· liver 
rejection. Transplant Proc 25:697, 1993. 
60 Friese CE, Hebert M, Osorio RW, et al. 
Maintenance immunosuppression with prednisone 
and RS-61443 alone following liver transplantation. 
Transplant Proc 25:1758-9,1993. 
61 Dumont FJ, Staruch MJ, Koprak SL, Melino MR, 
Sigal NH. Distinct mechanisms of suppression of 
murine T-cell activation by the related macrolides 
FK-506 and rapamycin. J Immunoll44:251-8, 1990. 
62 Dumont Fl, Melino MR, Staruch MJ, Koprak SL, 
Fisher PA, Sigal NH. The immunosuppressive 
macrolides FK-506 and rapamycin act as reciprocal 
antagonists in murine T-cells. J Immunol 144:1418-
24, 1990. 
63 Kay JE, Kromwel L, Doe SE, Denyer M. 
Inhibition of T and B lymphocyte proliferation by 
rapamycin. Immunology 72:544-9, 1991. 
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immunosuppressant in animal models. Because 
of its unique mechanism of action, clinical trials 
will be of great interest. 
Brequinar sodium 
Brequinar sodium is a substituted 5-
quinolone carboxylic acid derivative that has 
broad anti-tumor activity in mice. It inhibits 
dihyrdoorotate acid dehydrogenase in the de 
novo pyrimidine biosynthesis pathway, resulting 
in depletion of precursors for necessary for RNA 
and DNA synthesis. It inhibits proliferation of 
murine lymphocytes activated by various 
mitogens .. and arrests T-cell and B-cell 
replication, but it does not interfere with early 
events in T-cell activation such as cytokine 
production.64 It has been shown to be effective 
in prolonging heart, kidney, and liver allograft 
survival and has been used to induce tolerance 
to liver allografts in rats.65 The clinical 
potential of this agent is yet to be determined. 
Deoxyspergualin 
15-deoxyspergualin (DSPG) is an analog of 
spergualin, an anti-tumor metabolite produced 
64 Thomson AW, Woo J, Lemster B, Todo S, Fung 
JJ, Starzl TE. Potentiation of the antiproliferative 
activity of brequinar sodium for murine lymphocytes 
by exogenous cytidine. Transplant Proc 25:704-5, 
1993. 
65 Knoop M, Cramer DV, Chapman FC, Makowka 
L. Brequinar sodium suppresses liver allograft 
rejection and induces permanent tolerance in the rat. 
Transp1ant Proc 25:706-7, 1993. 
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by Bacillus laterosporus. It has been shown to 
have efficacy in clinical renal transplantation for 
treatment of acute rejection and for management 
of recipients of kidneys from ABO incompatible 
or preformed antibody positive donors. 66. 67 
The drug has a selecti ve effect on the 
differentiation pathway of B-Iymphocytes and 
suppresses competent proliferating T -cells, such 
as cytotoxic T-cells. However, unlike 
cyc1osporine and FK 506, DSPG does not affect 
IL-2 production or IL2-receptor expression.68, 69 
It has recently been shown that DSPG 
binds to a heat shock protein, Hsp70.70 
Members of the heat shock protein 70 family are 
66 Amemiya H, Suzuki S, Ota K, et al. A novel 
rescue drug, 15-deoxyspergualin. First clinical trials 
for recurrent graft rejection in renal recipients. 
Transplantation 49:337-43, 1990. 
67Takabasbi K, Tanabe K, Ocha S et al. 
Prophylactic use of a new immunosuppressive agent, 
deoxyspergualin, in patients with kidney 
transplantation for ABO-incompatible or preformed 
antibody positive donors. Transplant Proc 23:1078-
82, 1991. 
68 Morikawa K, Oseko F, Morikawa S. The 
suppressive effect of deoxyspergualin on 
differentiation of human B-Iymphocytes maturing 
into immunoglobulin producing cells. 
Transplantation 54:526-31, 1992. 
69 Fujii H, Nemoto K, Abe F, et al. 
Deoxyspergualin, a novel immunosuppressant, 
markedly inhibits mixed lymphocyte reaction and 
cytotoxic T-Iymphocyte activity in vitro. Int 
J ImmunopharamcoI14:731-7, 1992. 
70 Nadler sa, Tepper MA, Schacter B, Mazzucco 
CE. Interaction of the immunosuppressant 
dexoyspergualin with a member of the Hsp70 family 
of heat shock proteins. Science 258:484-6, 1992. 
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important to many cellular processes, including 
immune responses, and may represent a family 
of immunophilin binding proteins distinct from 
the cis-trans proline isomerases associated with 
the binding of cyclosporine and FK 506. This 
may explain the different mechanism of action 
of DSPG and the ability of this agent to act 
synergistically with cyclosporine or FK 506. 
The clinical efficacy of DSPG in liver 
transplantation remains to be established. 
Other agents 
So far, only a monoclonal antibody directed 
agai~st the CD-3 determinant of the T-cell 
receptor has found widespread application as a 
clinical immunosuppressive agent, and most of 
the drugs that are used in clinical practice have 
Immunology 
been products of serendipitous discovery. 
Efforts to explore the clinical potential of other 
monoclonal antibodies directed against the CD4 
determinant associated with helper T-cells, 
cytokine receptors, adhesion molecules, and 
"second signal" accessory molecules such as the 
CD28-B7 or CTI.A4-B7 complexes continue. 
As our understanding of the signal transduction 
pathways activated by antigen-receptor binding 
and drug-immunophillin binding on the surface 
of the T-cell continue to evolve, other methods 
of aborting or redirecting the immune response 
mechanism will be developed and our 
understanding of how to achieve and control the 
accommodation between donor and host 
necessary to maintain graft acceptance will be 
increased. 
INDICATIONS FOR LIVER TRANSPLANTATION 
The liver diseases that can benefit from 
liver transplantation can be grouped into four 
major categories: chronic end stage liver 
disease, hepatic malignancies, fulminant hepatic 
failure and inborn errors of metabolism (Table 
1). The evaluation of a potential liver transplant 
candidate varies markedly depending upon the 
specific disease indication for which liver 
transplantation is being considered. Thus, the 
initial goal in the evaluation process is to 
determine the correct diagnosis and etiology of 
the liver disease present in the candidate. This 
begins with a determination as to whether the 
patient has predominantly. hepatocellular or 
cholestatic liver disease (Table 2). All patients 
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who develop a complication of their liver 
disease should be referred to a transplant center 
for further evaluation and follow-up. The 
complications of interest include ascites, 
encephalopathy, coagulopathy, gastrOintestinal 
bleeding, hypersplenism with Clinically 
significant leucopenia and thrombocytopenia, 
severe fatigue, wasting or malnutrition, severe 
or disabling pruritus and liver associated bone 
disease (hepatic osteodystrophy). Once an 
individual has been identified as a potential liver 
transplant candidate, it is of paramount 
importance to stage the liver disease in order to 
define appropriately the timing of the procedure. 
The conventional criteria used to identify the 
Orthotopic Liver Transplantation 
ideal candidate for a liver transplant, and the 
optimal timing for the procedure are reported in 
Table 3. Evaluation of these issues gives an 
estimate of the synthetic, excretory and 
metabolic function of the liver, as well an 
assessment of the life quality of the individual 
with end stage Ii ver disease, and defines the 
transplant urgency. 
Not only is it important to identify 
candidates for liver transplantation, but it is also 
mandatory to screen each candidate for the 
presence of any absolute or relative 
contraindications to the procedure (Table 4). 
The contraindications for liver transplantation 
have been reduced through the years as a 
consequence of steady improvements in surgical 
technique and intraoperative and postoperative 
care. 
At present the only absolute 
contraindications include extrahepato-biliary 
sepsis, extrahepatic tumor or metastases, severe 
cardiopulmonary disease, and AIDS. The first 
of these is only a transient absolute 
contraindication. Once the sepsis is controlled, 
such patients can be given a transplant. In 
selected groups of patients, a careful screening 
for the presence of extrahepatic tumor is 
recommended: i.e., colon cancer in patients 
with primary sclerosing cholangitis (PSC), 
breast cancer in patients with primary biliary 
cirrhosis (pBC), head and neck cancer in 
subjects with a history of alcohol abuse. 
All patients evaluated for Ii ver 
transplantation require an accurate assessment of 
-18-
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the function of their other organ systems, 
particularly of the heart, lungs and kidneys 
(Table 5). In older patients (> 50 years), even in 
the absence of clinical cardiac symptoms, a 
cardiac ultrasound and a MUGA scan are 
indicated to identify subclinical cases of heart 
disease. In selected cases, a coronary 
arteriogram or a left or right sided cardiac 
catheterization may be required. Younger 
potential liver transplant recipients with specific 
liver diseases known to be associated with an 
increased incidence of heart disease also need to 
undergo a thorough cardiopulmonary evaluation. 
These include candidates with a possible 
cardiomyopathy associated with alcoholism, 
hemochromatosis, Wilson's disease, and 
glycogen storage disease or pulmonary 
hypertension in individuals with autoimmune or 
chronic cholestatic liver disease, alpha-! 
antitrypsin deficiency, or chronic active hepatitis 
C. 
The presence of pre-existing renal disease 
adversely effects transplant survival and often 
becomes a major postoperative problem. Thus, 
an accurate assessment of an individual's renal 
function prior to transplantation is mandatory. 
In cases with advanced renal disease, a 
combined liver-kidney transplant may be 
considered in selected cases.7l. 72 
71 Margreiter R, Kramar R, Huber C, et al. 
Combined liver and kidney transplantation (letter). 
Lancet 1: 1077-1078, 1984. 
72 Toussaint C, De Pauw L, Vienne A, et al. 
Radiological and histological improvement of 
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Specific Disease Indications 
Primary Biliary Cirrhosis (PBC) 
PBC represents an ideal indication for liver 
transplantation because of its slow and 
progressive evolution, which allows for a 
sufficiently accurate prediction of the ideal 
timing for surgery,73 In general, once the serum 
bilirubin level exceeds 10 mg/dl in symptomatic 
patients, survival averages less than 50% at two 
years. A more accurate index can be obtained by 
the evaluation of six readily available clinical 
parameters which can be used to produce a risk 
score that can be used to estimate the median 
survival of patients: These parameters include 
the patient's age, serum bilirubin level, serum 
albumin level, the presence of cirrhosis, the 
presence or absence of central lobular 
cholestasis and a history of prior treatment with 
azathioprine.74 
The general policy is to consider a patient 
ready for transplantation when the estimated life 
expectancy of the patient is predicted to be less 
than one year, unless complications of their liver 
oxalate osteopathy after combin6d liver-kidney 
transplantation in primary hyperoxaluria type 1. Am 
J Kidney Dis 21:54-63, 1993. 
73 Esquivel CO, ,Benardos A, Demetris AJ, et aI. 
Liver transplantation for primary biliary cirrhosis in 
76 patients during the cyclosporine era. 
Gastroenterology 94:1207-1216,1988. 
74 Neuberger J, Altman DG, Christensen E, 
Tygstrup N, Williams R. Use of a prognostic index 
in. evaluation of liver transplantation for primary 
biliary cirrhosis. Transplantation 41:713-6, 1986. 
-19-
Indications 
disease such as uncontrollable variceal bleeding, 
intractable itching or bone demineralization are 
adversely affecting the individual's quality of 
life and necessitate earlier transplantation. The 
current one-year survival rate for patients 
hospitalized for PBC at most centers ranges 
between 70% and 85%,75,76 
Primary Sclerosing Cholangitis (PSC) 
This disease shares many clinical 
similarities with PBC, particularly its slow 
progressive course with a late onset of the major 
complications of cirrhosis. The condition of 
patients with this disease is generally well-
maintained until very late in its course.77 For 
this reason individuals with PSC are usually 
considered excellent candidates for liver 
transplantation,78 Intractable itching, disabling 
pruritus, recurrent cholangitis? ascites, 
osteoporosis, and encephalopathy are the typical 
indications for transplantation. 
75 Starzl ru, Demetris AJ, and Van Thiel DH. 
Medical progress: Liver transplantation (Part ID. N 
Engl J Med 321:1092-1099,1989 
76 Starzl ru, Demetris AJ and Van Thiel DR. 
Medical progress: Liver transplantation (Part I). N 
Engl J Med 321:1014-1022, 1989. 
77 LaRusso NF, Wiesner RH, Ludwig J, et al. 
Primary sclerosing cholangitis. N Engl J Med 
310:899-903, 1984. 
78 Marsh JW Jr, Iwatsuki S, Makowka L, et al. 
Orthotopic liver transplantation for primary 
sclerosing cholangitis. Ann Surg 207:21-28, 1988. 
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An important association exists between 
PSC and ulcerative colitis.77 Therefore, a 
colonoscopic examination is mandatory prior to 
transplantation in order to exclude the presence 
of a colon cancer, which is known to occur more 
frequently in patients with ulcerative colitis. 
PSC is also strongly associated with an 
increased risk for cp.olangiocarcinoma (CCa).77 
Multiple (at least 3) percutaneous or endoscopic 
brushings of the biliary tree in an attempt to 
identify an occult cholangiocarcinoma in such 
cases are required prior to transplantation. 
Unfortunately, even with the use of combined 
radiologic and cytologic teChniques, the 
identification of a CCa in cases of PSC is very 
difficult, and the diagnosis is often made only 
after a pathologic examination of the removed 
Ii ver has been perfo~edK 
Once an individual with PSC is identified 
as a potential liver transplant recipient, invasive 
surgical procedures such as various biliary 
reconstructions and partial or total colectomy 
should be avoided because they may increase 
the technical, difficulty of the transplant 
procedure. 
The cUrrent one-year survival rate for 
patients ,transplanted for PSC ranges between 
70% and 80% in patients without previous 
surgery, as compared to a value of 50-60% in 
patients· with a history of prior biliary tract 
procedure.75, 76, 78 
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Autoimmune Chronic Acti~e Hepatitis 
(ACAH) 
This unpredictable liver disease is 
characterized by an extremely variable course, 
complicated by multiple recurrent episodes of 
"active hepatitis" which eventually lead to 
cirrhosis and all of its complications. Even in 
cases where an early diagnOSis and treatment is 
instituted with a powerful immunosuppressive 
agent, cirrhosis and hepatic decompensation is 
likely to occur. Thus, liver transplantation 
represents the therapy of choice for advanced 
ACAH. 
However, the unique behavior of this 
disease, which is characterized by exacerbations 
and remissions, makes the timing of the 
transplant procedure rather difficult. In many 
cases, the long-term use of immunosuppressive 
agents creates untoward effects such as bone 
demineralization, recurr~nt infections, sterold-
induced myopathy and obesity that become the 
impetus for transplantation. 
The current one-year survival for patients 
transplanted for ACAH ranges between 60% and 
90%.15. 76,79 
79 Sanchez UL, Czaja AJ, van Hoek n, Krom RA. 
Prognostic features and role of liver transplantation 
in severe corticosteroid treated autoimmune chronic 
active'hepatitis. Hepatology 15:215-21, 1992. 
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Alcoholic Liver Disease 
Alcohol abuse is the etiologic factor 
responsible for most of the liver disease in 
Western societies. Individuals with either 
Laennec's cirrhosis or alcoholic hepatitis are the 
largest group of potential candidates for liver 
transplantation at most transplant centers. 
Unfortunately, the scarcity of donor organs has 
caused many transplant centers to redefine their 
indications and contraindications for liver 
transplantation such that individuals with 
alcoholic liver disease are relatively 
disenfranchised as potential liver allograft 
recipients.80-84 Concerns about alcohol abuse 
recidivism and the potential for a lack of 
compliance with the post-transplant 
management, together with social prejudice and 
the adverse publicity associated with giving an 
alcoholic a donor organ in preference to a less ill 
80 Atterbury CE: The alcoholic in the lifeboat. 
Should drinkers be candidates for liver 
transplantation? 1 Clin GastroenteroI8:1-4, 1986. 
81 Gasbarrini A, Fagiuoli S, Gavaler IS, Azzarone S, 
Francavilla A, Van ThieIDH. Orthotopic liver 
transplantation for alcopolic liver disease. Alcologia 
4: 19-21, 1992. 
82 Killeen TK. Alcoholism and liver transplantation: 
ethical and nursing implications. Perspectives in 
Psychiatric Care 29:7-12, 1993. 
83 Knechtle SI, Fleming MF, Barry KL, et al. Liver 
transplantation for alcoholic liver disease. Surgery 
112:694-701,1992. 
84 Osorio RW, Freise CE, Ascher NL, et al. 
Orthotopic liver transplantation for end-stage 




non-alcoholic, have been raised and continue to 
be raised such that alcohol abuse has become a 
relative contraindication for liver 
transplantation. 83 
However, when acceptance of alcohol 
abuse as the etiology of the liver disease can be 
documented, with abstinence for more than 3 
months, recidivism and non-compliance are 
unusual. Moreover, the survival rate for 
individuals transplanted for alcoholic liver 
disease does not differ from that reported for 
patients transplanted for non-alcoholic end-stage 
liver disease. A recent study has reported that 
alcohol use after liver transplantation is. less 
common in patients transplanted for alcoholic 
liver disease than it is for patients transplanted 
for other disease indications.85 The recidivism 
rate is less than 15% in cases transplanted for 
end stage liver disease. Unfortunately, the 
recidivism rate is as high as 50% in the few 
transplanted for life-threatening alcoholic 
hepatitis. 
When an individual with alcoholic liver 
disease is evaluated for liver transplantation, the 
presence of specific, unique, alcohol-related 
contraindications, such as cerebral or cerebellar 
atrophy, cardiomyopathy and chronic 
pancreatitis, must be carefully assessed. These 
conditions can both increase the peri-operative 
85 Bonet H, Gavaler IS, Wright ill, Fagiuoli S, 
Gurakar H, Van Thiel DH. The effect of continued 
alcohol use on allograft rejection following liver 
transplantation ,for alcoholic liver disease. 
Gastroenterology 104:878, 1993. 
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risk and reduce the likelihood of a significant 
improvement in life quality following an 
otherwise successful transplant. 
The one-year survival rate of individuals 
transplanted for alcohol-related liver disease at 
most centers ranges between 75% and 85%.75.76. 
83- 85 
Virus-Related End-Stage Liver Disease 
End-stage liver disease occurring as a 
consequence of viral infection (HB V, 
HBVIDelta, HCV, and non-A, non-B, non-C) is 
the most common indication for liver 
transplantation worldwide. It is estimated that 
more than 30% of the world's liver transplant 
candidates have a disease which is related 
directly to a hepatotrophic viral infection. 
1n assessing patients with hepatitis B for a 
liver transplant, it is mandatory to determine the 
replicative status of the virus. In the absence of 
active viral replication (HBeAg- I HBVDNA-), 
liver transplantation is generally successful and 
disease recurrence is unusual; on the other hand, 
for those who have evidence of active viral 
replication (HBeAg+IHBVDNA+), a 100% 
recurrence rate is to be expected. Worse yet, the 
graft liver disease progresses at a rate much 
faster than the· original infection. For these 
reasons, active HBV infection currently 
represents a relative contraind~cation for liver 
transplantation. The one-year survival rate for 
individuals transplanted for active HBV disease 
ranges between 45-55%, compared to a figure of 
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70-80% in patients without evidence of active 
viral replication. 
Peri- and post~transplant therapy either 
with hyperimmune gammaglobulins, interferon 
and HBV vaccine, or a combination of these 
agents, delays the onset of recurrent disease and 
may prevent recurrence of the infection in the 
allograft if continued indefinitely. 86-89 
Treatment with alpha interferon (IFN) prior to 
transplantation, in an attempt to arrest HBV 
replication, has not influenced the rate of HBV 
reinfection after transplantation when compared 
to the rate observed in patients treated with anti-
HBs immunoglobulin alone.90 Continuous 
passi ve immunoprophylaxis after transplantation 
with an anti-HBs immunoglobulin (Ig) has 
reduced the 2-year actuarial rate of recurrence of 
86 Blumhardt G, Neuhaus P, Bechstein WO et al. 
Liver transplantation in HBsAg positive patients. 
Transplant Proc 22: 1517-1518, 1990. 
87 Gugenheim J, Crafa F, Fabiani P, et al. Long-tenn 
passive immunoprophylaxis of B virus recurrence 
after liver transplantation in HBs antigen-positive 
patients. Transplant Proc 25:1349-50, 1993. 
88 Lauchart W, Muller R, Pichlmayr R. Long tenn 
immunoprophylaxis of hepatitis B virus reinfection 
in recipients of human liver allografs. Transplant 
Proc 19: 4051-4053,1987. 
89 Mora NP, Klintmalm GB, Poplawski SS, et aI. 
Recurrence of hepatitis B after liver transplantation: 
Does hepatitis-B-immunoglobulin modify the 
recurrent disease? Transplant. Proceed 22: 1549-
1550,1990. 
90 Bismuth H, Azoulay D, Dennison A. Recent 
developments in liver transplantation. Transplant 
Proc 25:2191-94, 1993. 
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HBsAg in serum to less than 30% and can 
indefinitely maintain HBsAg seronegativity and 
HBVDNA negativity in graft biopsy specimens. 
In situ hybridization assays of liver biopsies 
may detect HBV genom a before the 
reappearance of HBsAg.91 However, even in Ig 
treated patients who remain seronegative for 
HBsAg and negative for HBVDNA negative in 
liver biopsies, HBVDNA is often detectable by 
PCR in peripheral blood mononuclear cells. 92 
In normal non-immunosuppressed 
individuals either co-infection or superinfection 
of HBV hepatitis with HDV is characterized by 
a more rapid progression to cirrhosis and/or 
liver failure than is seen in individuals with 
HBV infection alone. This appears not to be the 
case in liver transplant recipients.93 HDV 
infection recurs early after liver transplantation 
before any evidence for recurrent HBV infection 
or clinicallbiochemical hepatitis is present. In 
general, recurrent HDV infection is subclinical. 
91 oeyn~s M, Tricottet V, Samuel D, et at. Allograft 
biopsies in situ hybridization HBVDNA detection of 
serum HBsAg-repositive patients treated with anti-
HBV immunoprophylaxis after liver transplantation 
for HBV cirrhosis. Transplant Proc 25: 1347-48, 
1993. 
92 Feray C, Zignego AL, Samuel D, et al. Persistent 
hepatitis B virus infection on mononuclear blood 
cells without concomitant liver infection. The liver 
transplantation model. Transplantation 49: 1155-8, 
1990. 
93 Ottobrelli A, Marzano A, Smedile A, Recchia S, 
Salizzoni M, et al. Patterns of hepatitis delta virus 
reinfection and disease in liver transplantation. 
Gastroenterology 101: 1649-1655, 1991. 
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HDV infection in both non-immunosuppressed 
individuals and in immunosuppressed liver 
allograft recipients appears to suppress HBV 
replication. Interestingly, following liver 
transplantation, HDV infection only becomes 
clinically evident after recurrent HBV disease 
becomes evident; this rather strongly suggests 
that the delta virus cannot by itself be 
pathogenic, that it is able to replicate in the 
absence of HBV and that for HDV disease to 
occur clinically, clinically active HBV infection 
is required.94 
The mean survival of liver allograft 
recipients transplanted for HBVIHDV co-
infection has been reported to be as high as 
75%, which compares favorably to a figure of 
45-55% in HBVDNA positivelHDV negative 
recipients.75, 76, 93 
Hepatitis C virus disease accounts for even 
a greater number of tratlSplants than does HBV 
disease. With new methods to detect HCV 
infection, the incidence of HCV disease in 
individuals otherwise thought to have alcoholic, 
autoimmune or cryptogenic disease has been 
shown to range between 30%-70%. HCV 
disease, like HBV infection, can recur, but does 
so at a rate different than HBV disease. It must 
be remembered that infection and disease are not 
synonymous. The available data suggest. that 
94 Grendele M, Colledan M, Gridelli B et al. Does 
the experience with liver transplantation suggest tba~ 
hepatitis delta virus is not cytopathic? Transplant 
Proc 22:1551-1553, 1990. 
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almost 100% of HCV + recipients will 
experience a recurrent infection. Nonetheless, 
both graft and patient survival are good, ranging 
between 87% and 100% at two years in several 
different series. In contrast to a non-universal 
reinfection rate, on average only 1 out of 3 
HCV+ recipients will experience a clinical, 
biochemical, or histologic recurrent disease; 
moreover, when such occurs, it tends to be mild 
to moderate in severity. 95, 96 Recent evidence 
suggests that severe or multiple rejections 
episodes, especially those requiring treatment 
with antilymphocyte antibody, may result in a 
higher and earlier incidence of recurrent 
hepatitis C.97 
Fulminant Hepatic Failure 
Fulminant hepatic failure is a medical 
emergency and thus represents an urgent 
indication for liver. transplantation.98, 99 The 
95 Wright lL, Donegan E, Hsu HH, et al. Recurrent 
and acquired hepatitis C viral infection in liver 
transplant recipients. Gastroenterology 103:317-22, 
1992. 
96 Shah G, Demetris, AI, Gavaler JS, Lewis JH, 
Todo S, Van Thiel DH. Incidence, prevalence, and 
clinical course of hepatitis C following liver 
transplantation. Gastroenterology 103:323-9, 1992. 
97 Sheiner P, Eytan M, Kishikawa K, et al. Severe or 
multiple rejection episodes increase the incidence of 
early recurrent hepatitis [abstract]. Second Congress 
of the International'Liver Transplantation Society, 
Toronto, Canada, October 7, 1993 .. 
98 Mutimer DJ, Elias E. L,iver transplantation for 
fulminant hepatic failure. Prog in Liver Dis 10:349-
67,1992. 
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survi val of a patient transplanted for FHF 
depends upon the ability of the medical team to 
stabilize the patient while simultaneously 
establishing the correct diagnosis. 
The prognosis is greatly influenced by the 
etiology of the FHF. Patients with 
acetaminophen intoxication have a mortality rate 
of 20-30%, compared to a rate of 45-50% for 
those with HA V-or HBV -induced liver failure 
or a rate as high as 80% or more in cases of 
HCV, nonA, nonB, nonC hepatitis, halothane 
hepatitis, or fulminant Wilson's disease. 100 
Thus, there is no reason to temporarily delay a 
transplant procedure for an individual having 
one of these diseases. 
A grade III coma, a Factor V less than 
20%, a serum creatinine greater than 10 mgldl, a 
serum bilirubin level greater than 20 mgldl, and 
an age greater than 10 years are each indicators 
of a poor prognosis without liver 
transplantation. 101, 102 With each additional 
99 Pauwels A, Mostefa-Kara N, Florent C, et al. 
Emergency liver transplantation for acute liver 
failure. Evaluation of London and Clichy criteria. J 
Hepatology 17:124-7,1993. 
100 O'Grady JG, Alexander GJM, Thick M, Potter 
D, Calne RY, Williams R. Outcome of orthotopic 
liver transplantation in the aetiological and clinical 
variants of acute liver failure. Q J Med 69:817-24, 
1988. 
101 O'Grady JG, Alexander GJM, HayHan KM, 
Williams R. Early indicators of prognosis ,in 
fulminant hepatic failure. Gastroenterology 97:439-
445,1989. 
102 Van Thiel DR. When should a decision to 
proceed with transplantation actually be made in 
cases of fulminant or subfulminant hepatic failure: 
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factor, the prognosis worsens and the 
requirement for transplantation increases. The 
current I-year survival rate following liver 
transplantation for FHF ranges between 55% 
and 75%.99, 101 
Hepatic Malignancies 
The indications for Ii ver transplantation for 
individuals with hepatocellular carcinoma have 
decreased over the last 10 years as a result of the 
high rate of disease recurrence. From a surgical 
standpoint, individuals with hepatocellular 
carcinoma (HCC) are excellent candidates 
because of their age and their well-maintained 
hepatic function. As a consequence, their 
perioperative mortality and morbidity are low. 
Small, incidental tumors discovered after 
the removal of a cirrhotic liver rarely recur. 
However, HCC found prior to transplantation 
recurs in up to 80% of cases and does so as early 
as 3 months post-transplant; the average interval 
to detectable recurrent tumor is 12-18 months 
(median 8 months). 103 A fall in alpha-
fetoprotein is commonly seen after total 
hepatectomy and transplantation, but 
unfortunately does not predict that tumor will 
not recur. A bilobar distribution of tumor, the 
presence of cirrhosis, an infiltrative type of 
tumor, macroscopic vascular invasion and 
at admission to hospital or when a donor organ is 
made available? J Hepatology 17:1-2.1993. 
103 Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE. 
Role of liver transplantation in cancer therapy. Ann 
Surg 202:401-407, 1985. 
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I ymph node metastases are factors that 
independently predict tumor recurrence and, 
therefore, survival after transplantation for 
hepatic malignancy. 104 
Tumor size and multifocality are the most 
important determinants of outcome and are mot 
useful in patient selection. Single lesions less 
than 3-5 cm have the best prognosis. The 
Cambridge group has observed no recurrences in 
patients who received a transplant for single 
dominant lesions measuring less than 4 cm.lOS 
In Bismuth's experience, 3- year survival in 
patients with one or two small lesions 
measuring less than 3 cm was 83% after 
transplantation compared to 41% for patients 
treated with subtotal resection.90 The superior 
results with transplantation suggests that 
subtotal resection may miss small multifocal 
cancers that can be cured by total hepatectomy 
and transplantation. 
A combination of pre- and post-transplant 
intraarterial chemotherapy appears to increase 
the survival of patients ~ansplanted for HCC. 
104 Esquivel CO, Iwatsuki S, Marino JR, Markus 
BH, Van Thiel DH and Starzl TE. Liver 
transplantation for hepatocellular carcinoma and 
other primary hepatic malignancies. In: Trends in 
Gastroenterology. Sugahara K (ed.), Japan,. 323-
332, 1989. 
105 McPeake JR, O'Grady JG, Zaman S, et al. Liver 
transplantation for primary hepatocellular 
carcinoma: tumor ize and number determine 
outcome. J HepatoI18:226-34, 1993. 
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Current survival rates are 63% at 1 year, 42% at 
3 years, and 40% at 5 years. 106. 107 
The fibrolamellar variant of HCC usually 
occurs in a non- cirrhotic liver and in a young 
adult. It is also characterized by a slow rate of 
disease progression. Nonetheless, the rate of 
disease recurrence following liver 
transplantation ranges between 30% and 50%.75, 
76, 108 
The results with cholangiocarcinoma are 
even worse than those for individuals 
transplanted for HCC. Cholangiocarcinoma 
invariably recurs with a recurrence rate of 70% 
at 8 months, even when the tumor is well 
localized in a peripheral rather than a central 
location. The prognosis is even worse for hilar 
tumors, Which recur within 3 months in 100% of 
cases,?5,76, 104 
Uver transplantation may prolong overall 
survival in patients with either primary or 
metastatic neuroendocrine tumors of the 
pancreas or small bowel. Tumor recurrence, 
106 Carr BI, Selby R, Madariaga J, et al. Prolonged 
survival after liver transplantation and cancer 
chemotherapy for advance4-stage hepatocellular 
carcinoma. Transplant Proc 25: 1128-9, 1993. 
.107 Stone MJ, Klintmalm G, Polter D, Husberg B, 
Egorin MJ. Neoadjuvant chemotherapy and 
orthotopic liver transplantation for hepatocellular 
car~inomaK Transplantation 48:344-7,1989. 
108 Starzl JE, Iwatsuki S, pha~ BW Jr, et al. 
Treatment of fibrolamellar hepatoma with partial or 
total hepatectomy and transplantation of the liver. 
Surg Gynecol Obstet 162:145-148, 1986. 
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when it recurs, is usually evident within a year 
of the transplant procedure. 109 
Patients with hepatic sarcomas have an 
almost universal rate of tumor recurrence within 
months of the transplant procedure; the only 
exception to this is epitheliod 
hemangioendothelioma, which can have a long 
disease-free interval following liver 
transplantation. 110 
Uver transplantation has been performed 
rarely on patients with metastatic colorectal or 
breast cancer.lll, 112 In both cases, the results 
have been universally unsatisfactory. 
Biliary Atresia 
Biliary atres~a represents the most common 
indication for liver transplantation in children, 
109 Makowka L, Tzakis AG, Mazzaferro V, et al. 
Transplantation for the liver for metastatic endocrine 
tumors of the intestine and pancreas. Surg Gynecol 
Obstet 168:107-11, 19U~K 
110 Marino IR, Todo S, Tzakis AG, et al. Treatment 
of hepatic epithelioid hemangioendothelioma with 
liver transplantation. Cancer 62:2079-84, 1988. 
111 Huber C. Niederwieser D, Schonitzer D, 
Gratwohl A, Buckner D, Margreiter R. Liver 
transplantation followed by high-dose 
cyclophosphamide, total-body irradiation, and 
autologous bone marrow . transplantation for 
treatment of metastatic breast cancer: a case report. 
Transplantation 37:311-2, 1984.. 
112 Mazzaferro V, Dindzans V, Makowka L, Van 
Thiel DH. Approach to hepatic metastases from 
colorectal adenocarcinoma. Sem Liv Dis 8:247-253, 
1988. 
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accounting for more than half the transplant 
procedures which are performed in children. 113 
In the pre-transplant era the prognosis for 
children with biliary atresia was grim, having a 
survival rate of only 5% at 2 years. The 
introduction of the Kasai procedure has 
improved dramatically the short term prognosis. 
Unfortunately it is not a cure and many if not all 
surviving children develop cirrhosis with portal 
hypertension usually by the age of 5 years. 
Currently, liver transplantation represents 
only cure for biliary atresia. It remains 
somewhat controversial whether any surgical 
procedure, particularly those involving the 
biliary tree such as the Kasai procedure, should 
be done prior to a liver transplant in children 
with biliary atresia because of the high risk for 
cholangitis and technical complications. 
Because it is difficult to obtain a small size liver 
suitable for an infant, the Kasai procedure 
continues to be a bridge operation performed in 
order to allow the infant to grow large enough to 
undergo a safe transplant procedure. Living-
related donations, reduced size and split livers 
remain additional options. The survival of 
children with biliary atresia following liver 
transplantation is more than 80% at one year, 
with a 5-years survival rate greater than 75%.75. 
76.113 
113 Iwatsuki S, Shaw Bw Jr, Starzl 1E: Liver 




Budd Chiari Syndrome 
This syndrome is characterized by hepatic 
vein thrombosis occurring as either a primary 
disease condition or secondarily as a 
consequence of a systemic hypercoagulative 
disorder, usually a myeloproliferative disease. 
The clinical course of the Budd Chiari 
Syndrome is usually slow, with a gradual 
progression to liver failure OCCurring over 
several months to years. In rare cases, a rapid 
onset followed by a steady downhill course is 
observed. Acute Budd-Chiari syndrome may be 
managed by side-to-side portocaval or 
mesoatrial shunting. The presence of cirrhosis, 
intractable ascites and refractory gastrointestinal 
bleeding constitute indications for liver 
transplantation. The establishment of a correct 
etiologic diagnosis of the hepatic vein 
thrombosis is of paramount importance in the 
clinical management of the patient after 
transplantation, since conditions such as 
polycythemia vera, essential thrombocytosis or 
any of the other myeloproliferative diseases 
require life-long anticoagulation and or 
myelotoxic therapy.114 
Inborn Errors of Metabolism 
Inborn errors account for 25% of the liver 
transplants performed in children and,. an 
114 Campbell DA Jr, RoUes K, ~amienson N, et aI. 
Hepatic transplantation with perioperative and long 
term anticoagulation as treabnent for Budd-Chiari 
syndrome. Surg Gynecol Obstet 166:551-558, 1988. 
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occasional liver transplant in adults. llS• 116 The 
indication for liver transplantation in an 
individual with an inborn error of metabolism 
can be either : 1) a chronic hepatopathy 
occurring as a direct result of the metabolic 
defect, 2) a hepatopathy occurring as part of a 
systemic disease or, 3) failure of an organ other 
than the liver as a consequence of a metabolic 
defect peculiar to the liver that spares the liver 
but causes extrahepatic organ dysfunction. 
In the first case, the metabolic defect is 
corrected by the liver transplant alone. Examples 
are protein C and S deficiency, antithrombin III 
defiCiency, Wilson's disease, tyrosinemia, 
galactosemia, and glycogen storage disease 
types I and IV.76• 117.118 In the second case, the 
liver transplant will not eliminate the metabolic 
defect which is present also in other organs (Le., 
protoporphyria, Gaucher's disease, 
hemochromatosis), and a specific therapy should 
115 Esquivel CO, Marino IR, Fioravanti V, Van 
Thiel DH. Liver transplantation for metabolic 
disease of the liver: Gastroenterology Clift N Am 
17:167-175,1988. 
116 Starzl TE. Surgery for metabolic liver desease. 
In: Surgery of the liver. McDermott WV Jr, ed. 
Oxford: Blackwell Scientific, 127-36, 1989. 
117 Mieles LA, Esquivel CO, Koneru B, Makowka 
L, Van Thiel DR, Tzakis AG, Starzl TE. Liver 
transplantation for tyrosinemia. A review of 10 
cases from the University of Pittsburgh. Dig Dis Sci 
35:153-157, 1990. 
118 Stemlieb I. Wilson's disease: Indications for 
liver transplant. Hepatology 4: 155-175, 1984. 
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be continued after transplantation: 119-121 
Finally, in the last case, even if the hepatic 
disease is virtually absent and the metabolic 
defect affects other vital organs, liver transplant 
may reduce disease acceleration and is 
occasionally a clinical cure. Examples are 
familial hypercholesterolemia types I and IV, 
alpha I-antitrypsin. deficiency, urea-cycle 
deficiencies, and oxalosis.72• 122-124 
Survival rates for these conditions are 
among the highest for any disease indication 
following Ii ver transplantation. ll5• 116 
119 Pillay P, Tzoracloeftherakis E, Tzakis AG, 
Kakizoe S, Van Thiel DH, Starzl lE. Orthotopic 
liver transplantation for hemochromatosis. 
Transplant Proc 23:1888-1889, 1991. 
120 Powell LW. Does transplantation of the liver 
cure genetic hemochromatosis? J Hepatol 16:259-
61,1992. 
121 Smanik EJ, Tavill AS, Jacobs GH, et al. 
Orthotopic liver transplantation in two adults with 
Niemann-Pick and Gaucher's Disease: Implications 
for the treatment of inherited disease. Hepatology, 
17: 42-49, 1993. 
122 Hoeg IM, Starzl lE, Brewer HB: Liver 
transplantation for treatment of cardiovascular 
disease: Comparison with medication and plasma 
exchange in homozygous familiar 
hypercholesterolemia. Am J Cardiol 59:705-707, 
1987. 
123 Sokal EM, Ulla L, Harvengt C, et al. Liver 
transplantation for familial hypercholesterole~ia 
before the onset of cardiovascular complications. 
Transplantation 55:432-3, 1993. 
124 Van Thiel DH, Starzl TE. a-I-antitrypsin 
deficiency and liver transplantation. In: Alpha 1-
antitrypsin Deficiency. Len.fant C (ed), NIH 
Monograph, Bethesda, MD, 1992. 
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PRE-TRANSPLANT ASSESSMENT AND PROGNOSTIC PARAMETERS 
Several parameters which indicate 
deterioration· or decompensation of end stage 
liver disease require continued reassessment 
during the pretransplant follow-up of a liver 
transplant candidate. A change in any of these 
parameters constitutes disease progression and 
an increased need for transplantation. The 
specific parameters to be followed in such cases 
are: 1) hepatic and renal function, 2) 
coagulation status, 3) the individual's metabolic 
and nutritional status, 4) the patient's 
microbiologic and immunologic status, 5) the 
candidate's neurologic status and 6) other 
peculiar problems. 
Hepatic and Renal Function 
An increase in either the serum bilirubin or 
the serum creatinine level associated with the 
onset of ascites and/or encephalopathy 
represents significant disease progression and 
enhances the risk of perioperative mortality. 
The serum electrolytes and particularly the 
serum sodium level are an important prognostic 
parameter; a serum sodium level less than 125 
mmollL should be corrected prior to a liver 
transplant procedure. It is important to note that 
a rapid correction of hyponatremia can produce 
central pontine myelinolysis. . Hepatorenal 
syndrome (HRS) is reversible after liver 
transplantation and patient survival is 
comparable in patients with and without HRS 
before operation. However, renal function in the 
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first 12 weeks after surgery may be worse in 
patients with HRS.125 
Coagulopatby 
During the preoperative period, a 
coagulopathy, particularly when associated with 
portal hypertension, constitutes a serious risk for 
gastrointestinal bleeding. As a reSUlt, 
coagulation parameters should be monitored 
closely, and the candidates awaiting liver 
transplantation may require intermittent 
infusions of fresh frozen plasma rich in 
coagulation factors. 
Metabolic and Nutritional Status 
Malnutrition in the cirrhotic patient is 
multifactorial and occurs as a consequence of 
asthenia, malabsorption, reduced hepatic protein 
synthesis, recurrent hospitalization and 
infectious episodes. Every patient included on a 
liver transplant candidate list should be 
evaluated for nutlltional deficits and have such 
deficits treated. A determination of how to 
provide the proper amount of protein and 
calories is important. Thus, the serum albumin , 
prealbumin, TIBG (Total Iron Binding 
Globulin), liposoluble vitamins (A, D, E and K) 
125 Seu P, Wilkinson AH, Shaked A, Busuttil RW. 
The hepatorenal syndrome in liver transplant 
patients. Amer Surgeon 57:806-9, 1991. 
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and trace elements levels should be monitored 
periodically. 
Immunity and Microbiologic Function 
The hypergammaglobulinemia typical of 
the cirrhotic state occurs as a result of an 
increase in the stimulation of B cells with portal 
systemic shunting and impaired Kupffer cell 
removal of portal venous antigens. Despite the 
apparent hypergammaglobulinemia, B cell 
function is often reduced and specific immune 
globulin levels, such as those against HBV, may 
be reduced, in part as a result of a defect in T 
cell-mediated immune regulation. Moreover, 
the complement system, the number and 
function of circulatory phagocytes, and the fixed 
reticuloendothelial system of the liver are all 
compromised. Malnutrition further aggravates 
these immune problems. . 
As a consequence, the cirrhotic patient is at 
increased risk for bacterial, fungal and viral 
infections. During the perioperative period, 
liver transplant candidates and recipients should 
have surveillance cultures of the pharynx, 
urinary, and gastrointestinal tracts, ascitic fluid 
and female genital tract. Serologic tests for 
cytomegalovirus, the herpes viruses, herpes 
zoster, Epstein-Barr. virus, toxoplasmosis, 
Treponema pallidum, and various fungal 
infections (Aspergillus fumigatus, candida, 
chlamydia, histoplasma) should be monitored as 
well. A tuberculin test and appropriate control 
skin tests are .also re~ommendedK 
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Vaccination against HBV and 
pneumococcus should be performed as a routine 
in all candidates. During the fall months the use 
of an influenza vaccine is recommended. 
Neurologic Status 
All liver transplant candidates should 
undergo a careful neurologic evaluation and 
follow-up examination to include both cli~cal 
(physical examination and ammonia levels) and 
instrumental assessment. EEG, visual and 
auditory evoked potentials and, in selected 
cases, CT scanning of the head should be 
performed. During the preoperative period, 
episodes of hepatic encephalopathy need to be 
treated aggressively with intestinal 
decontamination and laxatives (neomycin, 
paromomycin, lactulose) and a reduction in 
dietary protein intake. 
Other Peculiar Problems 
In older patients (> 50 years), even in the 
absence of clinically evident cardiac symptoms, 
a cardiac ultrasound and a MUGA test should be 
performed routinely. Cardiomyopathies, often 
not detected clinically without specific testing, 
are known to occur frequently in patients with 
chronic cholestasis and in individuals with 
alcoholic and familial (Wilson's disease, 
hemochromatosis, glycogen storage disease) 
disorders of the liver. In such cases, special 
attention to the cardiac evaluation is warranted. 
Certain liver diseases, such as alpha-l-
antitrypsin deficiency, cystic fibrosis, 
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autoimmune chronic active hepatitis, HeV and 
HBV hepatitis, have a higher incidence of 
pulmonary disease than present in the general 
population consisting of a spectrum of 
obstructive, restrictive and vascular diseases 
which necessitate preoperative evaluation. 
Obviously all pulmonary infections must be 
treated and must be resolving, if not cured, prior 
to transplantation. 
The presence of pulmonary hypertension 
with a right ventricular pressure above 50 
mmHg is associated with a poor intra-operative 
prognosis and requires special attention on the 
part of the anesthesiologist prior to and during 
the transplant operation. 126-128 Intrapulmonic 
shunts which develop in cirrhotic patients are 
reversible, but the patient may require prolonged 
postoperative ventilatory support. 129, 130 
126 Plevak D, Krowka M, Rettke S, Dunn W, 
Southom P. Successful liver transplantation in 
patients with mild to moderate pulmonary 
bypertension. Transplant Proc 25: 1840, 1993. 
127 Prager MC, Cauldwell CA, Ascher NL, Roberts 
IP, Wolfe CL. Pulmonary hypertension associated 
with liver disease is not reversible after liver 
transplantation. Anesthesiology 77:3754-8, 1992. 
128 Scott V, De Wolf A, Kang Y, et al. Reversibility 
of pulmonary hypertension after liver 
transplantation: a case report. Transplant Proc 
25: 1789-90, 1993. 
129 Erikson LS, SOderman C, Ericzon B-G, Eleborg 
L, Wahren J, Hedenstiema G. Normalization of 
ventilation/perfusion relationships after liver 
transplantation in patients' with decompensated 
cirrhosis: evidence for a hepatopulmonary 
syndrome. Hepatology 12:1350-57, 1990. 
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Management Of Chronic Hepatic 
Disease Complications Prior To 
Liver Transplantation 
Encephalopathy 
A moderate protein diet consisting of 0.75 
to 1.0 g proteinlkglday body weight is 
recommended for most patients. Salt restriction 
is required for most also. Water restriction is 
required for those with hyponatremia with 
serum sodium levels less than 130 mEqlL. 
Lactulose or a milk containing diet in those 
with lactose intolerance is used most widely. 
The goal with either is·to obtain 2-4 soft bowel 
movements per day. Larger doses can produce 
dehydration, acidosis and various electrolyte 
abnormalities. 
Recently, oral prostaglandin El has been 
used to enhance intestinal transit and increase 
renal blood flow, both of which reduce the 
nitrogenous substrate loads that contribute to the 
syndrome of hepatic encephalopathy. 
EsophageaVGastric Varices 
Large varices of the esophagus (grade 3 or 
4) or of the stomach are at risk for bleeding 
while patients wait for a donor organ. Patients 
with a history of prior bleeding or those .with 
signs of an increased risk of bleeding, such as 
130 Scott V, Miro A, Kang Y, et al. Reversibility of 
the hepatopulmonary syndrome by orthotopic liver 
transplantation. Transplant Proc 25:1787-88, 1993 .. 
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hemocytic spots, red spots and whale lines, can 
be treated either with esophageal sclerotherapy 
or varix banding. The latter method is preferred 
if the varices are not actively bleeding. 
Sclerotherapy is reserved to control active 
bleeding because of its increased risk of 
prodUcing a focus of infection in or about the 
esophagus, either high in the abdomen or in the 
inferior mediastinum. 
Patients with bleeding that cannot be 
controlled easily with sclerotherapy, or 
individuals who cannot be maintained free of 
recurrent bleeding, can be treated successfully 
with a transjugular intrahepatic shunt (TIPS), a 
useful bridge to transplantation in patients with 
variceal hemorrhage or refractory ascites. l3l-133 
Distal spleno-renal and mesocaval shunts, which 
avoid the hepatic hilum, are preferred to 
conventional portacaval shunts when surgery to 
control variceal hemorrhage is necessary. In 
general, shunt procedures should be reserved for 
patients who have good hepatic reserve and who 
are not expected to require transplantation in the 
131 Richter GM, Noeldge G, Palmasz JC, and 
Roessle M. The transjugular intrahepatic 
portosystemic stent-sh!lnt (TIPS): result of pilot 
study. Cardiovascular and Interventional Radiology 
13:200, 1990. 
132 Woodle ES, Darcy M, White HM, et aI. 
Intrahepatic porto systemic vascular stents: a bridge 
to hepatic transplantation. Surgery 113:344-51, 
1993. 
133 LaBerge 1M, Ring ~I Gordon RL. Creation of 
transjugular intrahepatic portosystemic shunts with 
the waIIstent endoprosthesis: results in 100 patients. 
Radiology 187:413-20, 1993. 
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foreseeable future. Esophago-gastric 
devascularization procedures may produce 
severe scarring in the upper abdomen and should 
be avoided in potential transplant candidates. 
All patients who bleed should be placed on 
either omeprazole or an H2 blocker and receive 
oral antibiotics in an effort to limit mucosal 
injury and prevent the development of either a 
gram negati ve bacteremia or spontaneous 
bacterial peritonitis as a result of bacterial 
translocation. 
Ascites 
Minor and moderate grades of ascites do 
not specifically require treatment. Large volume 
or massive ascites is treated with large doses of 
spironolactone and a loop diuretic such as 
furosemide. In severe cases, particularly those 
with rapidly recurring ascites or those with a 
prior history of spontaneous bacterial peritonitis, 
serial large volume peritoneocentesis or a 
transjugular intrahepatic portasystemic shunt 
(TIPS) procedure can be used to manage the 
ascites. 
Renal Dysfunction 
Individuals with advanced liver disease 
occasionally have co-existent renal disease and 
many have functional renal dysfunction related 
to their underlying liver disease. The best 
methods to prevent functional renal impainnent 
are the avoidance of non-steroidal anti-
inflammatory agents for pain, the maintenance 
of an adequate vascular volume with albumin 
--,---- ------
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and/or other colloid infusions and, if necessary, 
the use of dopamine infusions. The latter is 
often complicated by the production of 
hypotension. In such cases, the combined use of 
dopamine plus an a-adrenergic vasoconstrictor 
such as noradrenaline may be required. 
Pre-transplant Management 
Dialysis should be considered if the serum 
creatinine exceeds 2.5 mgldl and may be 
necessary if the serum creatinine level exceeds 
2.0 mgldl if hepatic encephalopathy is also a 
problem. 
ORGAN DONATION AND PRESERVATION 
Donor availability and selection 
The dramatic improvement in results after 
liver transplantation and an expanded list of 
indications for the procedure has created a 
significant increase in the demand for organ 
donors. Estimates of the available supply, of 
donor organs ranges from 6,900 to 9,600 per 
year. In 1991, 3,182 livers were procured, an 
estimated procurement efficiency of 33% to 
61 %,l34 
Over the past several years, the rate of 
organ donation has remained level (Figure 2). 
Although the donor I><?ol has been expanded by 
more liberal criteria for donor selection, by 
improvements in organ preservation, and by use 
of reduced size grafts; at the same time 
improved care of trauma victims and effective 
road safety programs (Figure 3), including 
increased use of seat belts (Figure 4), have had 
an opposite impact. As a result median waiting 
134 Orlans CE, Evans RW, Ascher NL. Estimates of 
organ-specific . donor availability for the United 
States. Transplant Proc 25:1541-2, 1993. 
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time of candidates for liver transplantation has 
increased (Figure 5), but this has not yet resulted 
in a significant increase in the rate of death of 
patients on the waiting list (Figure 6). 
Donor and recipient matching for liver 
transplantation is mainly based on ABO 
compatibility and estimated liver size. Height 
and weight are usually used to match a donor 
with a reCipient, with appropriate allowances for 
abnormal liver size in the reCipient as 
determined preoperatively by imaging studies. 
Thoracic circumference is also a indicator of 
liver size and is used by some centers in 
estimating donor liver volume. 
Immunological criteria 
Except for ABO compatibility, 
immunological criteria have not been applied to 
the selection of liver donors.. As p~eviously 
discussed, the traditional . donor-specific 
antibody crossmatch that is a prohibitive ,barrier 
in renal transplantation is not 'used for liver 
donor-selection. 
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Early studies suggested that HLA-matching 
had either no impact on survival or a 
paradoxical beneficial effect on liver grafts, with 
slightly better survival seen in those patients 
who received an HLA-mismatched graft. 135, 136 
More recent studies have suggested a slight 
survival advantage for HLA-A and HLA-B 
matched grafts, but no effect has been found for 
DR matching. 137, 138 The highly effective 
immunosuppression used in liver 
transplantation, together with improvements in 
non-immunological factors, including surgical 
technique and patient management, have 
contributed to improved patient survival in 
recent years and may mask the lesser effects of 
HLA matching, reducing its importance to 
overall outcome. 
Cytomegalovirus 
Cytomegalovirus infection is a common 
complication in immunosuppressed patients, but 
135 Adler M, Gavaler JS, Duquesnoy ru, et al. 
Relationsbip between the diagnosis, preoperative 
evaluation, and prognosis after liver transplantation. 
Ann Surg 208: 196-202, 1988. 
136 Markus BH, Duqesnoy RJ, Gordon RD, et al. 
Histocompatibility and liver transplant outcome. 
Does HLA exert a dualistic effect? Transplantation 
46:372-7,1988. 
137 Yagibasbi A, Kobyashi M, Noguchi K, et al. 
HLA matching effect in liver transplantation. 
Transplant Proc 24:2432-33, 1992. 
138 Kobayashi M, Yagibasi A, Noguci K, et al. 
HLA-DR matcbing effect in in orthotopic liver 
transplantation under FK 506. Transplant Proc 
25:228-9, 1993. . 
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the mortality of CMV infection has been 
dramatically reduced since the introduction of 
ganciclovir (see discussion below). Although 
there is an increased risk for development of 
CMV infection with grafts from CMV 
seropositive donors, no significant adverse 
effect of CMV infection on patient or graft 
survival is seen. Therefore, given the current 
organ donor shortage, CMV serologic matching 
of donors and reCipients is neither practical nor 
worthwhile. 139 
Viral hepatitis 
More difficult questions concern the use of 
liver donors with a history of exposure to 
hepatitis viruses. In the case of hepatitis B, 
patients positive for hepatitis B surface antigen 
should not be used. It is probably also wise to 
avoid patients with elevated IgM titers of 
hepatitis B core antibody. 
Whether or not it is reasonable to use livers 
from donors with measurable IgG core antibody 
remains to be determined. Some organs from 
such donors may be used preferentially in HBV 
DNA positive recipients, or in individuals 
known to be "immune" to hepatitis B as 
manifested by high titers of anti-HBsAg 
antibody. Some small risk of HBV DNA 
transfer with organs from such donors does exist 
139 Stratta RJ, Wood RP, Langnas AN, et al. Donor 
selection for orthotopic liver transplantation: lack of 
an effect of gender or cytomegalovirus (CMV) 
status. Transplant Proc 22:410-13, 1990. 
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and could result in a disease exacerbation, 
possibly due to a strain of virus contained in the 
donor organ different from that previously 
experienced by the recipient. 
Considerable controversy exits concerning 
the use of liver grafts from patients with 
significant titers of antibody to hepatitis C virus 
(HCV). The prevalence of hepatitis C 
seropositivity among organ donors is reported to 
be 2%.140 The first generation ELISA assay 
used to detect hepatitis C antibody has a high 
false positive rate. As a result, efforts to 
determine the actual rate of transmission of 
hepatitis C through organ donation based on 
results of this assay may underestimate the risk. 
Second and third generation tests have higher 
specificity. 
Even using the relatively non-specific first 
generation ELISA assay, the incidence of 
seropositivity for hepatitis C in a large 
population of VOluntary blood donors in Spain 
was only 1.2%, but among these seropositive 
patients, 70% were confirmed to be seropositive 
by a second generation RIBA assay. Among 105 
confirmed seropositive donors for whom liver 
biopsy was available, 21 % had persistent 
140 Pereira BJG, Milford EL, Kirkman RL, et al. 
Evidence of bepatitis e virus RNA in organ donors 
positive for hepatitis e antibody and in the 




chronic hepatitis, 45% had chronic active 
hepatitis, and 7% had active cirrhosis. 141 
A similar report from Italy also found a 
high incidence of abnormal histological findings 
in the livers of voluntary blood donors 
confirmed to be hepatitis C antibody positive by 
a second generation RIBA assay. 142 
Furthermore, the New England Organ Bank has 
reported a high incidence of positive PCR for 
HCV RNA in organ donors with a positive first-
generation ELISA for anti-HCV, and high 
incidence of conversion from negative to 
positive PCR in recipients of an organ from an 
HCV PCR positive donor. 140 However, the 
Miami transplant group has reported a low 
incidence of mortality and morbidity from liver 
disease in kidney reCipients who received organs 
from confirmed hepatitis C positive donors. 143 
Since the overall incidence of hepatitis C in 
the organ donor population is small and there is 
increasing evidence that many seropositive 
donors are infectious, it is prudent to avoid use 
of liver grafts from hepatitis C seropositive 
141 Esteban n, L6pez-Talavera Je, Genesca J, et al. 
High rate of infectivity and liver disease in blood 
donors with antibodies to hepatitis e virus. Ann Int 
Med 115:443-9, 1992. 
142 Alberti A, Chemello L, Cavaletto D, et al. 
Antibody to hepatitis C virus and liver disease in 
volunteer blood donors. Ann Int Med 114:1010-
1012, 1991. 
143 Roth D, Fernandez JA, Babischkin S, et al. 
Detection of hepatitis. C virus infection among 
cadaver organ donors: evidence for low transmission 
of disease. Ann Int Med 117:470-475, 1992. 
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donors except in urgent circumstances. The 
antibodies detected with current assay 
techniques are not neutralizing antibodies and 
have no protective effect. Furthermore, there is 
good experimental evidence demonstrating that 
there are multiple strains of hepatitis C virus and 
that prior infection with one strain does not 
necessarily protect against infection by another 
strain, or even reinfection by the same strain. 144 
Assessment of organ viability 
At the present time, there is no single, 
convenient test that is relied upon to predict 
donor organ quality or graft viability prior to 
implantation. The conversion of lidocaine to 
monoethylglycinexHde (MEGX) by the liver has 
been shown to correlate with conventional tests 
of hepatic function and can be measured quickly 
and inexpensively.145 The sensitivity of the 
MEGX values has been reported to be only 65% 
and therefore the test is less reliable at 
determining that a liver should be discarded 
when the MEGX level is IOW.146 Grafts from 
donors with a MEGX less than 50 nglmL should 
be considered to be at high risk of poor function 
144 Farci P, Alter ill, Govindarajan S, et al. Lack of 
protective immunity against reinfection with 
hepatitis C virus. Science 258:135-140, 1992. 
145 Ollerich M, Burdelski M, Ringle B, et al. 
Lignocaine metabotite formation as a measure of 
pre-transplant liver function. Lancet 1:640, 1989. 
146 Adam R, Azoulay D, Astarcioglu I, et al. Limits 
of the MEGX test in selection of liver grafts for 
transplantation. Transplant Proc 25:1653-4, 1993. 
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and correlation should be sought with other 
selection criteria, including liver biopsy. 146, 147 
ICG clearance, arterial ketone body ratio 
(AKBR), and hyaluronic acid levels in the 
venous effluent of the graft have all shown some 
Significant correlation with postoperative graft 
function. 148-150 Pre-transplant biopsy is also 
important, but is not infallible, since irreversible 
subcellular damage is easily missed with 
conventional histology. Significant fatty 
infiltration with macrovesicular steatosis, 
hydropic degeneration of hepatocytes, and 
peri central or panlobular individual hepatocyte 
necrosis are indicative of increased risk of poor 
147 Tesi RJ, Elkhammas EA, Davies EA, et al. Safe 
use of liver donors with MEGX values less than 90 
ng/mL. Transplant Proc 25: 1655-56, 1993. 
148 Osaki N, Ringe B, BunzendalIl H, et al. 
Postoperative recovery of mitochondrial function of 
the human liver graft procured and preserved with 
University of Wisconsin solution. Transplant Int 
3:128-32, 1990. 
149 Yamaoka Y, Wasbida M, Manaka D, et al. 
Arterial ketone body ratio as a predictor of donor 
liver viability in human liver transplantation. 
Transplantation 55:92-5, 1993. 
150 Rao PN, Bronsther 0, Pinna A, et al. Prediction 
of early graft function by effluent levels of 
hyaluronic acid in clinical liver transplantation. 
Transplant Proc 25:2141-2, 1993. 
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graft function.151-153 Fatty change is frequently Exclusion criteria 
associated with obesity, alcohol ingestion, 
diabetes, nutritional disorders, drug use, and 
advanced age, but often without significant 
abnormalities of conventional liver function 
tests. However, fatty livers do not appear to 
tolerate the preservation process well and are at 
high risk of severe dysfunction and failure after 
transplantation. 
Transplantation of a liver from a donor 
with a prolonged stay in an intensive care unit 
prior to organ donation has also been associated 
with poor graft function. This may be related to 
depletion of glycogen stores in the graft as a 
result of nutritional depletion and additional 
depletion of glycogen by anaerobic metabolism 
in grafts with a long preservation time. Whether 
or not deliberate repletion of glycogen prior to 
preservation and transplantation can ameliorate 
this phenomenon needs further study.l54 
151 Todo S, Demetris A, Makowka L, et al. Primary 
nonfunction of hepatic allografts with preexisting 
fatty inftltration. Transplantation 47:903, 1989. 
152 D' Alessandro A, Kalayoglu M, Sollinger HW, et 
al. The predictive value of donor liver biopsies for 
the development of primary nonfunction after liver 
transplantation. Transplantation 51:157-63,1991. 
153 Markin RS, Wood RP, Stratta RJ, et al. 
Predictive value of intraoperative biopsies of donor 
organs in patients undergoing orthotopic liver 
transplantation. Transplant Proe 22:418-9, 1990. 
154 Adam R, Reynes M, Bao YM, et al. Impact of 
glycogen content of the donor liver in clinical liver 
transplantation. Transplant Proc 25:1536-7, 1993. 
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The age range of organ donors has 
expanded in recent years and is generally term 
newborn to 65 years of age with acceptable 
results. 155. 156 However, fatty infiltration is 
more common in older donors and MEGX 
values tend to be lower. Therefore, organs 
obtained from older donors should be carefully 
evaluated for abnormal histology and the 
preservation times of organs from such donors 
should be kept as short as possible.157 Impaired 
early graft function and cholestasis are often 
seen with livers from older donors; these 
transient problems, however, are not associated 
with increased long term graft loss.158. 159 
Other donor selection criteria include: 
155 Adam R, Astarcioglu I, Azoulay D, et al. Age 
greater than 50 years is not a contraindication for 
liver donation. Transplant Proc 23:2602-3, 1991. 
156 Wall WJ, Mimeault R, Grant DR, Bloch M. The 
use of older donor livers for hepatic transplantation. 
Transplantation 49:377-81, 1990. 
157 Adam R, Astarcioglu D, Azooulay D, et al. Liver 
transplantation from elderly donors. Transplant Proc 
25:1556-57, 1993. 
158 Adam R, Astarcioglu D, Azoulay D, et al. Liver 
transplantation from elderly donors. Transplant Proc 
25:1556-57, 1993. 
159 Buckel E, Sanehez-Urdazpal J, Steers "J, et aI. 
Impaired initial function in liver grafts from donors 
> 50 years of age. Transplant Proc 25: 1558-59, 
1993. 
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• Absence of sepsis, or any 
transmissible disease 
• No malignancy (except for minor 
skin cancers) 
• No history of intravenous drug 
abuse 
• Known cause of death 
• No preexisting hepatic disease 
• No significant trauma to the liver 
• Normal or near normal (and 
preferably improving) liver function 
tests (pT, PTT, SGOT, SGPT, 
bilirubin - the outer limits of 
acceptability depend upon clinical 
profile of the donor and urgency of 
the potential recipient). 
In donors who have sustained a severe 
ischemic episode, the kidneys are usually more 
sensitive to ischemia than is the liver. If the 
kidneys are still producing urine, the liver is 
usually viable. A transient rise in liver 
aminotransferase enzymes is often found and is 
acceptable if repeat values show improvement. 
Severe hypematremia (serum sodium > 160 
mEq/L) is not well tolerated by the liver and 
may be found in donors who have been severely 
dehydrated for management of brain swelling. 
Ideally, every cadaver donor should have 
an autopsy to determine the presence of 
conditions, espeCially malignancies, that might 
be transmitted by an organ graft to the recipient. 
However, in practice, permission for such an 
examination is often denied or the examination 
cannot be performed expeditiously enough to be 
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of clinical use. 160 Choriocarcinoma has been 
transmitted from a single donor to both a liver 
and two kidney recipients. 161 Based on this 
report, it is worthwhile to test female donors of 
childbearing age who have a history of irregular 
menstruation or a recent pregnancy or 
spontaneous abortion for HCG levels to rule out 
this possibility. 
It is common practice to accept organs 
from donors with cerebral neoplasms, unless a 
ventriculoperitoneal shunt has been placed, as 
these lesions typically kill by their intracranial 
mass effect rather than by metastatic spread. 
Nonetheless, transmission of an intracerebral 
neoplasms from a donor to an organ graft 
recipient has been reported. 162, 163 For this 
reason ,we do not routinely recommend the use 
of livers obtain~d from donors with malignant 
intracerebral neoplasms, unless an autopsy can 
establish that the lesion is confined to the brain. 
160 Penn I. Malignancy in transplanted organs. 
Transplant Int 6:1-3, 1993. 
161 Marsh JW, Esquivel CO, Makowka L, et al. 
Accidental transmission of malignant tumor from a 
donor to multiple recipients. Transplantation 
44:449-50, 1987. 
162 Lefrancois N, Touraine JL, Cantarovich D, et al. 
Transmission of medulloblastoma from cadaver 
donor to organ transplant recipients. Transplant Proc 
19:2242, 1987. 
163 Morse JH, Turcotte JG, Merion RM, et al. 
Development of a malignant tumor in a liver 
transplant graft procured from a donor with a 
cerebral neoplasm. Transplantation 50:875-77, 1990. 
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Alcohol abuse 
Donors with a history of alcohol abuse and 
elevated blood alcohol levels are acceptable for 
organ donation if liver function is good and liver 
histology is nonnal. There is no correlation 
between an elevated blood alcohol level and 
subsequent initial graft function or 30-day graft 
survival. 164 
Organ procurement and 
preservation 
The basic techniques of organ procurement 
and graft implantation were developed over a 
twenty-five year period at the University of 
Colorado and later at the University of 
Pittsburgh. Procurement of a whole liver graft 
from a brain dead, heart beating cadaver donor 
remains the main source of organs. This is 
usually perfonned as part of a multiple organ 
procurement in which the kidneys, heart, lungs, 
and pancreas are all removed for transplantation. 
However in recent years, in addition to reduced 
size and split liver grafts from heart beating, 
brain dead donors, liver segments from living 
related donors are being used to compensate for 
the demand for organs for infants and small 
164 Hassanein TI, Gavalier JS, Fishkin D, Gordon R, 
Starzl IE, Van Thiel DH. Does the presence of a 
measurable blood alcohol level in a potential organ 
donor affect the outcome of liver transplantation? 
Alcohol Clin Exp Res 15:300-3, 1991. 
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children. The surgical techniques of organ 
retrieval are well described.165.167 
Belzer and associates in 1987 introduced a 
new preservation solution, the University of 
Wisconsin (UW) solution, which has permitted 
a significant prolongation of the cold storage 
time for cadaver liver grafts. 168,169 UW solution 
differs from Euro-Collins in that it contains 
adenosine, allopurinol, raffinose, hydroxyethyl 
starch, and lactobionate. UW solution offers 
better protection of the microvasculature of the 
liver from reperfusion injury. It contains no 
glucose and does not support continued 
anaerobic glucose metabolism during cold 
storage of the liver. Its osmotic properties 
reduce the graft swelling that is seen after 
preservation in Euro-Collins. 
165 Starzl IE, Hakala TR, Shaw BW Jr, et al. A 
flexible procedure for multiple cadaveric organ 
procurement. Surg Gynecol Obstet 158:223, 1984. 
166 StarzlIE, Miller C, Broznik B, and Makowka L. 
Ao improved technique for multiple organ 
harvesting. Surg Gynecol Obstet 165: 343; .. 8, 1987. 
167 Casavilla A, Gordon RD, and Starzl TE. 
Techniques of Liver Transplantiation. In: Surgery of 
the liver and Biliary Tract. Blumgart LH, ed. 
Churchill Livingston, London, in press. 
168 Kalayoglu M, Sollinger HW, Stratta RI, et aI. 
Extended preservation of the human liver for 
clinical transplantation. Lancet 1:616, 1988. 
169 Belzer FO, D' Allesandro AM, Hoffman RM, et 
aI. The use . of UW solution in clinical 
transplantation. A 4-year experience. Ann. Surg 
215:579-83, 1992. 
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Extension of the safe cold storage time for 
liver grafts has many practical logistic 
advantages, including more time for recipients 
to get to the transplant center, for transport of 
grafts from distant centers, for preparation of 
reduced liver grafts, and for switching to a 
"back-up" recipient if the first intended recipient 
is found to be unsuitable, as well as for semi-
elective scheduling of cases during regular 
working hours. 
Although successful preservations have 
been obtained after as much as 30 hours of cold 
storage in UW solution, it is now apparent that 
there are risks to extending the cold ischemia 
time beyond 12 to 18 hours. The incidence of 
graft loss in the Pittsburgh experience was found 
to increase significantly when organ 
preservation was extended beyond 18 hours. 170 
Bismuth has reported better initial graft function 
and long term outcome in patients whose liver 
grafts were preserved in UW solution for less 
than 12 hourS.!7l The Mayo Clinic group 
reported a correlation between the incidence of 
nonanastomotic biliary strictures and the length 
of the cold ischemia time for livers preserved in 
either Euro-Collins or UW solution. This 
observation has been confirmed in subsequent 
170 Furukawa H, Todo S, Imventarza 0, et al. Effect 
of cold ischemia time on the early outcome of 
human hepatic allografts preserved with UW 
solution. Transplantation 51: 1000-4, 1991. 
171 Adam R, Bismuth H, Diamond T, et al. Effect of 
extended cold ischemia with UW solution on graft 
function after liver transplantation. Lancet 
340: 1373-6, 1992. 
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studies. In. 173 Thus, it is important to minimize 
cold storage time. 
In Sanchez UL, Gores GJ, Ward EM, et al. 
Ischemic type biliary complications after orthotopic 
liver transplantiation. Hepatology 16:49-53, 1992. 
173 Kadmon M, Bleyl J, Kuppers B, Otto G, and 
Herfarth C. Biliary complications after prolonged 
University of Wisconsin solution preservation of 
liver allografts. Transplant Proc 25:1651-2, 1993. 
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SURGICAL TECHNIQUE 
The recipient operation consists of the 
removal of the native liver, vascular 
anastomosis of the veins and arteries of the graft 
to the recipient vessels (anhepatic phase), 
hemostasis, and biliary reconstruction. In 
patients with previous upper abdominal surgery 
or multiple prior episodes of spontaneo~s 
bacterial peritonitis, highly vascularized 
adhesions may make the recipient hepatectomy 
very difficult. For this reason, operations in the 
upper abdomen should be avoided, whenever 
possible, in potential liver transplant candidates. 
A complete description of operative 
technique is beyond the scope of this chapter 
and has been provided elsewhere. 167 The 
following will highlight the essential features of 
the operation. 
Abdominal incision and exposure 
OrthotopiC liver transplantation is most 
commonly performed through a bilateral 
subcostal incision with an upper midline 
extension. In infants and small children, the 
upper midline extension is usually not needed. 
In patients with extensive prior surgery or 
multiple adhesions, in patients requiring 
exposure of the infrarenal aorta for 
reconstruction of the hepatic arterial supply, and 
in tumor patients in whom an extended 
dissection is to be performed, a lower midline 
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extension may be added. Thoracic extensions 
are rarely needed. 
In pediatric patients and in many adults, a 
"hockey stick" approach using an upper midline 
incision with lateral extension at a level just 
above the umbilicus to just· beyond the right 
mid-axillary line may be used. This approach 
provides better access to the infrarenal aorta 
when exposure is needed for reconstruction of 
the hepatic artery and is less disfiguring than the 
standard bilateral subcostal incision. However, 
in patients with a massively enlarged liver or a 
large left lobe, extensive prior abdominal 
surgery, or in those requiring concomitant 
splenectomy, the incision may need to be 
extended to the left. 
The approach to remove the native liver is 
determined by the conditions encountered at 
surgery. In most cases, a hilar dissection is 
performed first, followed by mobilization of the 
hepatic lobes and exposure. of the suprahepatic 
and infrahepatic portions of the inferior vena 
cava. 
Veno:-venous bypass 
The most critical stage of the recipient 
operation is the anhepatic phase, during which 
removal of the diseased liver is completed and 
the vascular reconstruction of the graft is 
performed. Interruption of the portal vein and 
vena cava results in complete blockage of the 
Orthotopic Liver Transplantation 
venous outflow from the splanchnic bed and 
lower. body. Without a bypass, severe renal, 
splanchnic and systemic venous hypertension 
and congestion can occur with sequestration of 
venous blood, reduced cardiac filling pressure, 
swelling of the intestines, renal dysfunction, and 
increased bleeding from congested venous 
collaterals. 
A partial veno-venous bypass was 
developed in Pittsburgh to prevent the 
physiological trauma of the anhepatic phase 
(Figure 7).174 With this technique, outflow 
cannulas are inserted into the portal and the 
femoral veins allowing both splanchnic and 
systemic blood to return to the heart by way of 
an inflow cannula placed in the axillary vein. A 
centrifugal-force pump is used to maintain flow 
rates of 1.5 to 3.5 Umin. Flows of at least 3.0 to 
3.5 Umin may be necessary to maintain a renal 
perfusion pressure of 50 mm Hg or higher. 175. 
176 Veno-venous bypass is used routinely for 
adult patients. Infants and small children 
174 Denmark SW, Shaw BW Jr, Griffith BP, Starzl 
TE. Venous-venous bypass without systemic 
anticoagulation in canine and human liver 
transplantation. Surg Forum 34:380, 1983. 
175 Scherer R, Giebler R, Schmutzler M, Erhard J, 
Lange R, Kox WJ. Shuntflow vs renal perfusion 
pressure during venovenous bypass in human 
orthotopic liver transplantation. Transplant Proc 
25:2590, 1993. 
176 Scherer R, Giebler R, Schmutzler M, Erhard J, 
Lange R, Kox WJ. Effect of high shuntflows during 
portofemoro-subclavian venovenous bypass in 
human orthotopic liver transplantation. Transplant 
Proc 25:2591, 1993. 
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weighing less than 15 kg tolerate venous 
occlusion reasonably well. The risks oflow rates 
of blood flow through the bypass and of 
pulmonary emboli outweigh the benefits of 
bypass in the majority of pediatric cases. 
With the traditional approach, the 
infrahepatic portion of the iruerior vena cava is 
removed with the native liver. However, an 
alternative approach is to dissect the liver off the 
vena cava, leaving the native vena cava with a 
cuff of hepatic veins behind for anastomosis to 
the suprahepatic vena cava of the graft (Figure 
8).177 In some cases, this "piggyback" technique 
can avoid the need for venous bypass, as the 
recipient vena cava remains intact. However, 
this method requires a more difficult caval 
dissection. 
The vascular anastomoses 
Once the native liver has been removed and 
hemostasis has been obtained in the exposed 
retroperitoneal bare area, the implantation of the 
graft begins with anastomosis of the 
suprahepatic vena cava (Figure 9). This is 
followed by anastomosis of the infrahepatic 
vena cava. The portal vein is flushed with cold 
electrolyte or colloid solution as the infrahepatic 
vena cava is sewn to flush the potasSium rich 
preservation solution out of the graft and to 
177 Tzakis A, Todo S, Starzl TE. Orthotopic liver 
transplantation with preservation of the inferior vena 
cava. Ann Surg 210:649-52, 1989. 
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remove air from the vena cava prior to 
revascularization. 
In the conventional approach to 
reconstruction, the portal vein reconstruction is 
performed next, after which venous inflow and 
outflow is restored to the graft. However, an 
experienced surgeon may elect to proceed first 
with reanastomosis of the hepatic artery, as the 
field is often relatively dry at this point, 
facilitating exposure of this most demanding 
part of the vascular reconstruction. The most 
common method of hepatic arterial 
revascularization is an end-to-end anastomosis 
of the donor celiac trunk to the recipient 
common hepatic artery at the level of the 
gastroduodenal artery takeoff. 
Extra-anatomic arterial reconstructions, 
usually involving a conduit of donor iliac artery 
from the infrarenal or supraceliac aorta, are 
often used for infants and small children and for 
adults with unsuitable native vessels. The usual 
origination of such a graft is an end-to-side 
anastomosis to the infrarenal aorta (Figure 10). 
The graft is then tunneled through the transverse 
mesocolon and passed in the avascular plane 
anterior to the pancreas and posterior to the 
stomach to reach the hepatic hilum for an end--
to-end anastomosis to the donor hepatic 
artery.178 Alternative sites for the origin of the 
arterial graft are the supraceliac aorta and the 
178 Tzakis AG, Todo S, Starzl 1E. The anterior 
route for arterial graft conduits in liver 
transplantation. Transplant Int 2: 121, 1989. 
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right iliac artery. Patency rates for these extra-
anatomic reconstructions, when used in primary 
transplantations, are comparable to conventional 
hepatic artery reconstruction and are superior 
when used for retransplantations. 179 
Long standing portal hypertension results 
in pathological changes in the wall of the portal 
vein that eventually may progress to 
thrombosis. 180 Organized thrombosis, atrophy, 
friability or cavernous transformation of the 
portal vein may make the main portal vein 
unusable. In some cases, declotting of the portal 
vein may be attempted. If this not feasible and 
the confluence of the mesenteric and splenic 
veins is patent, an interposition vein graft 
(usually iliac vein from the liver donor) may be 
used to bridge the gap between the donor and 
reCipient portal veins. 
If neither the native portal vein nor its 
confluence can be used, a mesoportal '1ump 
graft" of donor iliac vein is used to create a new 
portal vein (Figure 11).181. 182 The graft is 
179 Hennein HA, Mendeloff EN, Turcotte JG, et al. 
Aortic revascularization of orthotopic liver 
allografts: indications and long-term follow-up. 
Surgery 113:279-85. 1993. 
180 Stieber AC, Zetti G, Todo S, et al. The spectrum 
of portal vein thrombosis in liver transplantation. 
Ann-Surg. 213:199. 1991. 
181 Sheil AGR, Thompson JF, Stevens MS, et al. 
Mesoportal graft for thrombosed portal vein in liver 
transplantation. Clin Transplantation 1: 18-9, 1987. 
182 Tzakis A, Todo S, Stieber A, Starzl1E. Venous 
jump grafts for liver transplantation in patients with 
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anastomosed end-to-side to the superior 
mesenteric vein and tunneled through the 
transverse mesocolon and the avascular plane 
between the stomach and pancreas to reach the 
hepatic hilum. The graft is then joined end-to-
end to the donor portal vein. 
Biliary reconstruction 
Most patients with end stage cirrhosis have 
some degree of coagulopathy with 
thrombocytopenia, prolonged prothrombin time, 
and . low fibrinogen levels prior to 
transplantation. A low grade fibrinolysis is also 
common, but hyperfibrinolysis is most often 
encountered after reperfusion of the Ii ver graft. 
This has been attributed both to increased 
endothelial release of tissue type plasminogen 
activator (t-PA) and decreased hepatic clearance 
of endogenous t-PA during the anhepatic phase 
of surgery.l83 Terpstra has reported that the 
increase in fibrinolysis seen during orthotopic 
liver transplantation, is not seen with heterotopic 
grafting. 184 This suggests that reduced 
clearance oft-PA during the anhepatic phase is a 
major contributor to hyperfibnnolysis. 
portal vein thrombosis. Transplantation 48:530, 
1989. 
183 Dzik WH, Arkin CF, Jenkins RL, Stump DC. 
Fibrinolysis during liver transplantation in humans: 
role of tissue-type plasminogen activator. Blood 
71:1090-5, 1988. 
184 Bakker CM, Metselaar Ill, Groenland TN, et aI. 
Increased tissue-type plasminogen activator activity 
in . orthotopic but not heterotopic liver 
transplantation: the role of the anhepatic period. 









use of the 
or specific 
coagulation factor assays, and component 
specific replacement of clotting factors (fresh 
frozen plasma, cryoprecipitate, factor VIII 
concentrate, and platelet transfusions) is 
essential. 185 Administration of antifibrinolytic 
agents (aprotinin or episilon-arninocaproic acid) 
may be required to correct hyperfibrinolysis. 
Neuhaus has demonstrated an advantage to 
giving aprotinin as a continuous infusion during 
surgery. 186 
In difficult cases, especially in patients with 
severe portal hypertension or extensive prior 
surgery, hours of tedious work may be required 
to obtain hemostasis. Once hemostasis is 
achieved, the biliary reconstruction is 
performed. Two methods are commonly used: 
duct-to-duct reconstruction over aT-tube stent 
and end-to-side anastomosis of the donor duct to 
a Roux-en-Y limb of proximal jejunum (Figure 
12). 
The donor gallbladder is removed. T -tubes 
across a duct -to-duct anastomosis are left in 
place for two to three months following surgery, 
185 Kang YG, MArtin DJ, Marquez J, et aI. 
Intraoperative changes in blood coagulation and 
thromboelastographic monitoring in liver 
transplantation. Anesth Analg 64:888, 1985. 
186 Himmelreich G, Muser M, Neuhaus P, et aI. 
Different aprotinin applications influencing 
bemostatic changes in orthotopic liver 
transplantation. Transplantation 53: 132-6, 1992. 
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but are usually clamped within seven to ten days 
of operation to improve bile flow into the 
intestine. An internal silastic biliary stent is 
usually placed across a choledochojejunostomy 
and will eventually pass spontaneously through 
the GI tract. 
A third method, use of the donor 
gallbladder as a conduit between donor and 
recipient ducts, is an alternative when a Roux-
en-Y choledochojejunostomy cannot be done 
because of previous intestinal resection or 
prohibitive adhesions. However, biliary stone 
and sludge formation are common after this 
method of reconstruction and it is rarely used. I87 
Reduced size liver transplantation 
The concept of ex vivo hepatic resection to 
produce a size compatible graft was initially 
developed at the University of Colorado in 1975 
when a 23 month old boy was given the left 
lateral segment of an adult liver. More recently, 
at centers in Brussels, Chicago, Hanover and 
Paris, the method has been reintroduced and 
shown to produce results approaching those 
achievable with whole liver transplantation. I88-
187 Halff G, Todo S, Hall R. Late complications 
with gallbladder conduit biliary reconstruction after 
liver transplantation. Transplantation 48:537, 1989. 
188 Bismuth H, Houssin D. Reduced-sized 
orthotopic liver graft in hepatic transplantation in 
children. Surgery 95:267-70, 1984. 
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191 Reduced liver grafts are usually implanted 
using the piggyback method described 
previously. 
Transplantation of two liver fragments 
from a single donor to separate recipients was 
first used successfully in Australia, but has since 
been used at other centers in the United States, 
Europe, and Japan.I92-195 The "split liver" graft 
is a very demanding technique and it remains to 
be established whether the incidence of technical 
complications and the durability of both 
fragments justifies this approach. So far, one-
189 Broelsch CE, Emond JC, Thistlethwaite JR, et 
aI. Liver transplantation with reduced-sized organs. 
Transplantation 45:519, 1988. 
190 OUe JB, Ville de Coyet J, Sokal E, et aI. Size 
reduction of the donor liver is a safe way to alleviate 
the shortage of size-matched organs in pediatric 
liver transplantation. Ann Surg 211:146, 1990. 
191 Strong R, Ong TH, Pillway P, et al. A new 
method of segmental orthotopic liver transplantation 
in children. Surgery 104:104-7, 1988. . 
192 Strong RW, Lynch SV, Ong TH, Matsunami H, 
Koido Y, Balderson GA. Succsessful liver 
transplantation from a living donor to her son. N 
Engl J Med 24:322: 1505-7, 1990. 
193 Broelsch CE, Emond JC, Whitington PF, et al. 
Application of reduced size liver transplants as split 
grafts, auxilary orthotopic grafts, and living related 
segmental transplants. Ann Surg 212:368-75,1990. 
194 Moreno Gonzales G, Gomez SR, Garcia GI, et 
al. Utilization of split liver grafts in orthotopic liver 
transplantation. Hepatogastroenterology 40: 17-20, 
1993. 
195 OUe JB, Ville de Goyet, Alberti D, et al. The 
concept and technique of the split liver in clinical 
transplantation. Surgery 107:605-12, 1990. 
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year patient survival with split Ii ver grafting is 
about 50%, which unfavorably compares with 
the results obtained with whole organ grafting.90 
Recently the technique of reduced size liver 
grafting has been extended to the use of a Ii ver 
segment from a living related donor in an effort 
to further extend the pool of available organs for 
pediatric recipients. 196, 197 Although the limited 
results available with this technique so far are 
good, the concept of jeopardizing the life of a 
healthy donor for the benefit of a diseased 
reCipient is controversial. There has been one 
death of a living related liver donor as a result of 
a postoperative pulmonary embolus. 
196 Broelsch CE, Edmond Ie, Whitington PF, et aI. 
Application of reduced-size liver transplants as split 
grafts, auxilary orthotopic grafts, and living 
segmental transplants. Ann Surg 212:368-75, 1990. 
1:97 Ozawa K, Uemoto S, Tanaka K, et aI. An 
appraisal of pediatric liver transplants from living 
·relatives. Initial clinical experience in 20 pediatric 
liver transplantations. Ann Surg 216:547-53, 1992. 
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POSTOPERATIVE MANAGEMENT 
Early postoperative recovery 
The postoperative course is dependent upon 
the preoperative condition of the patient, the 
difficulty of the operative procedure, and the 
function of the graft. Patients who go to 
operation in good nutritional status, who have 
an uneventful operation with minimal or 
moderate blood loss, and those whose graft 
functions well can be expected to recover 
quickly and to require only 24 to 48 hours of 
postoperative intensive care. Patients with 
advanced muscle wasting, a prolonged operation 
with high blood loss, intrapulmonic shunts 
(hepatopulmonary syndrome), severe renal 
insufficiency, or poor early graft function 
predictably have a more protracted recovery. 
Most patients arrive in the recovery unit 
with significant excess fluid volume, but 
oliguria is common in the initial 24 to 48 hours 
after surgery. As a result, diuretics and colloid 
infusions (fresh frozen plasma or albumin) are 
often needed. As mentioned above, some centers 
use antilymphocyte preparations for induction 
immunosuppression in the early postoperative 
period to avoid the use of nephrotoxic 
immunosuppressive agents, such as 
cyclosporine or FK 506. Crystalloids should be 
limited to maintenance fluids to avoid 
pulmonary edema. Narcotic and sleep 
medications should be avoided until good graft 
function is established and the patient is alert. 
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Hypertension is a serious management 
problem in the early postoperative period when 
patients are still in a coagulopathic state, are 
often thrombocytopenic, and are at increased 
risk of intracerebral bleeding. It should be 
treated aggressively. Nifedipine, p-blockers 
(labetolol, propanolol), and hydralazine are first 
line drugs. Nitroglycerine or nitroprusside 
infusions are used in more severe cases. 
Continued bleeding after surgery must be 
treated promptly. Coagulation is monitored 
closely after surgery including platelet count, 
prothrombin time, fibrinogen levels, factor VIII, 
and D-dimers or euglobulin lysis time. 
Appropriate measures should be taken to correct 
disturbances if the patient is bleeding. Re-
exploration is advocated for all patients who 
bleed after surgery if the abdomen is distended 
or imaging studies show an abdomen containing 
a significant volume of clotted blood. All 
vascular anastomoses should be carefully 
examined and all clot should be evacuated from 
the abdomen during such explorations. 
In a stable patient, a restrained approach to 
the correction of coagulopathy is recommended. 
A prothrombin time within 15 seconds of 
control and platelet counts as low as 
30,OOO/mm3 are acceptable. Overcorrection of a 
moderate coagulopathy and overtransfusion in a 
stable patient may contribute to thrombosis of 
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the hepatic artery.198 In small children, who are 
at higher risk of hepatic artery complications, 
anticoagulation with Dextran 40 and aspirin and 
persantine is recommended. Patients who 
receive a transplant for Budd-Chiari syndrome 
should be started on an antithrombosis protocol 
as soon as they are stable and graft function is 
ensured. 
Primary graft failure 
Good liver function after surgery is 
indicated by spontaneous correction of 
coagulopathy, stable blood glucose, declining 
serum lactate levels, improving urine output, 
and improving mental status. If a T-tube is 
present, the quantity and quality of bile 
production can also be monitored. Deteriorating 
mental status, hyperkalemia, alkalosis, and 
hypoglycemia indicate severe graft failure. Low 
levels of coagulation factors V and VII are 
commonly found in patients with graft 
failure. 199 If poor graft function is suspected, a 
Doppler ultrasound study of the hepatic vessels 
should be obtained to assess patency of the 
portal vein and hepatic artery. Potassium 
infusions should be avoided and 10% dextrose 
in water should be administered. Continuous 
198 Buckels JA, Tisone G, Gunson BK, McMaster P. 
Low haematocrit reduces hepatic artery thrombosis 
after liver transplantation. Transplant Proc 21:2460-
1,1989. 
199 Bilik R, Superine RA, Poon AO. Coagulation 
plasma factor levels are early indicators of graft 
nonfunction following liver transplantation. J Pediat 
Surg 27:302-6, 1992. 
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intravenous infusion of prostaglandin El 
(pGEl), which may have beneficial effects in 
fulminant hepatic failure and graft preservation, 
has been reported to be useful in the treatment 
of primary graft dysfunction.200, 201 However, 
one recent prospective randomized trial failed to 
demonstrate a beneficial effect of perioperative 
PGEI infusions on reperfusion injury.202 
Ultimately, only urgent retransplantation 
can save the patient with irreversible ischemic 
injury from sepsis or irreversible brain swelling. 
In extreme circumstances, removal of a necrotic 
graft with the creation of a temporary portocaval 
shunt may stabilize the patient briefly until a 
new graft can be implanted, typically within 48 
hours.203, 204 
200 Greig PD, Woolf GM, Abecassis M, et al. 
Treatment of primary liver graft nonfunction with 
prostaglandin E1. Transplantation 48:447-53, 1989. 
201 Isai H, Sheil AG, McCaughan G, Dolan P, 
Waugh R. Successful reversal of primary graft non-
function in a liver transplant patient treated with 
prostaglandin E1. Aust N Z J Surg 62:314-6, 1992. 
202 Alevizacos P, Belchstein WO, Roussaint R, 
Neuhais P. Failure of PGEI to prevent liver allograft 
reperfusion injury in a prospective randomized trial. 
Transplant Peoc 25:2545-6, 1993. 
203 Ringe B, Pichlmayr R, Lubbe N, Bomscheuer A, 
Kuse E. Total hepatectomy as a temporary approach 
to acute hepatic or primary graft failure. Transplant 
Peoc 21:3822-41, 1989. 
204 So SKS, Barteau JA, Perdrizet GA, Marsh JW. 
Successful retransplantation after a 48-hour 
anhepatic state. Transplant Peoc 25:1962-3,1993. 
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Prior to the introduction of UW solution for 
liver preservation, primary graft failure was a 
precipitous event occurring within the first week 
after surgery. Postperfusion biopsies may show 
zonal or severe focal necrosis. A neutrophilic 
exudate may be present and suggests the 
possibility of hyperacute rejection. The results 
of the donor specific antibody crossmatch 
should be assessed if such findings are observed. 
A more insidious fonn of primary graft 
failure with persistent cholestatic jaundice and 
eventual fibrosis of the portal tracts has been 
seen in recent years. Typically, these patients 
show evidence of severe hepatocellular injury 
with high aminotransferase levels in the first 
few days after surgery. However, despite a rapid 
fall in aminotransferase activity, cholestatic 
jaundice persists and gradually worsens in the 
ensuing weeks. Biopsies typically show no 
evidence of rejection, but expansion of the 
portal tracts with increasing fibrosis and areas of 
centrilobular necrosis are seen. 
Postoperative Management 
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COMPLICATIONS 
Technical complications 
Technical complications, especially biliary 
tract and vascular complications, remain a 
significant problem and are responsible for 10% 
of graft losses and 8% of the patient mortality 
seen after liver transplantation.205 Mortality at 6 
months after transplantation is 32% in patients 
who suffer a surgical complication, compared to 
11 % in patients without such complications.206 
Vascular 
Hepatic artery. Thrombosis of the hepatic 
artery is the most common vascular 
complication seen after liver transplantation. In 
the two largest. reported seri,es from Pittsburgh 
and from Omaha, the incidence of hepatic artery 
thrombosis was 6.7% and 6.3%, respectively.205, 
207 The highest risk of arterial thrombosis is 
associated with a recipient or donor weight of 
less than 15 kg and a long cold ischemic 
205 Lerut J, Gordon RD, Iwatsuki S, Starzl IE. 
Surgical complications in human orthotopic liver 
transplantation. Acta Chir Belg 87:193-204, 1987. 
206 Lebeau G, Yanaga K, Marsh J, et al. Analysis of 
surgical complications after 397 hepatic 
transplantations. Surg Gynecol Obstet 170:317-22, 
1990. 
207 Langnas AN, Marujo W, Stratta RJ, Wood RP, 
Shaw BW Jf. Vascular complications after 
orthotopic liver transplantation. Am J Surg 161:76-
82; 1991. 
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time. 208, 207 Causes include technical failures, 
preservation injury, overly aggressive correction 
of coagulopathy, a high hematocrit, post-
transplant hypercoagulability, severe allograft 
rejection, and postoperative pancreatitis. 198, 
209-212 
Graft arterial thrombosis has three general 
patterns of presentation: 1) fulminant hepatic 
gangrene; 2) delayed biliary leak with or 
without bile abscess; 3) relapsing bacteremia 
with minimal, if any, liver dysfunction.213 It 
should be suspected in any patient with a 
208 Tan K, Yandza T, de Hemptinne B, C1apuyt P, 
Claus D, Oue JB. Hepatic artery thrombosis in 
pediatric liver transplantation. J Pediat Surg 23:927-
30,1988. 
209 Yanaga K, Makowka L, Starzl IE. Is hepatic 
artery tllrombosis after liver transplantation really a 
surgical complication? Transplant Proc 21:3511-3, 
1989. 
210 Stalll RL, Duncan A, Hooks MA, et aI. A 
hypercoagulable state follows orthotopic liver 
transplantation. Hepatology 12:553-8, 1990. 
211 Mazzaferro V, Esquivel CO, Makowka L, et al. 
Hepatic artery thrombosis after pediatric liver 
transplantation - a medical or surgical event? 
Transplantation 47:971-7, 1989. 
212 Badger I, Buckels JA. Hepatic artery thrombosis 
due to acute pancreatitis following liver 
transplantation. Transplantation 48:526-7, 1989. 
213 Tzakis AG, Gordon RD, Shaw BW Jr, Iwatsuki 
S, Starzl 1E: Clinical presentation of hepatic artery 
thrombosis after liver transplantation in the 
cyclosporine era. Transplantation 40:667-71, 1985. 
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postoperative fever and elevation of liver 
function tests. Blood cultures which grow 
enteric organisms such as Klebsiella species, 
Escherichia coli, or enterococci are almost 
pathognomonic. 
Doppler ultrasound is an effective 
screening device. However, arteriography 
should be obtained whenever the diagnosis of 
hepatic artery thrombosis is strongly suspected 
on clinical grounds, even if the Doppler study is 
reported to show arterial flow, since hepatopedal 
arterial collaterals may develop and result in a 
misinterpretation of the Doppler study.214. 215 A 
reversed or absent diastolic Doppler flow Signal 
may be found early after transplantation and is 
not a reliable predictor of subsequent hepatic 
artery thrombosis. 216 Also, in patients such as 
children with very small vessels, both Doppler 
flow studies and arteriography may give false-
positive findings. Rollins et al have described 
four pediatric reCipients less than 26 months of 
age with Doppler flow and angiographic studies 
2I4Flint ~I Sumkin ill, Zajko AB, Bowen A. Duplex 
sonography of hepatic arterial thrombosis after liver 
transplantation. Am 1 Roentgenol 151:481-3, 1988. 
215Hall TR. McDiarmid SV, Grant SV, Boechat MI, 
Busuttil RW. False negative duplex Doppler studies 
in children with hepatic artery thrombosis after liver 
transplantation. Am 1 Roentgenol 154:573-5, 1990. 
216 Propeck PA, Scanlan KA. Reversed or absent 
hepatic arterial diasto~ic flow in liver transplants 
shown by duplex sonography: a poor predictor of 
subsequent hepatic artery thnnbosis. Am J 
Roentgenol159: 1199-201, 1992. 
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suggesting hepatic artery thrombosis who were 
found to have patent vessels at autopsy.217 
Treatment of hepatic artery thrombosis 
depends upon both the etiology and the clinical 
presentation. Stable patients without persistent 
sepsis, bile leak, or bile abscess can often be 
maintained on an oral antibiotic for a prolonged 
period of time. Intrahepatic biliomas resulting 
from hepatic artery thrombosis can be initially 
managed with percutaneous drainage. Although 
progression of multiple ischemic biliary 
strictures may eventually necessitate 
retransplantation, patients treated by 
interventional radiology and medical therapy 
often avoid retransplantation for several 
years. 218.219 
If massive liver injury has not occurred, 
early technical failures can sometimes be 
salvaged by immediate surgical correction or by 
fibrinolytic therapy followed by transluminal 
angioplasty for correction of an underlying 
217 Rollins NK, Timmons C, Superina RA, Andrews 
WS. Hepatic artery thrombosis in children with liver 
transplants: false-positive findings at Doppler 
sonography and arteriography in four patients. Am J 
Roengenol 160:291-4, 1993. 
218 Hoffer FA, Teele RL, Lillihei CW, Vacanti JP. 
Infected bilomas and hepatic artery thrombosis in 
infant recipients of liver transplants. Interventional 
radiology and medical therapy as an alternative to 
retransplantation.'Radiology 169:435-8, 1988. 
219 Kaplan SB, Zajko AB, Koneru B. Hepatic 
bilomas due to hepatic artery thrombosis in liver 
transplant recipients: percutaneous drainage and 
clinical outcome. Radiology 174:1031-5, 1990. 
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arterial stricture. 220, 221 Fulminant hepatic 
necrosis requires retransplantation. In severe 
cases, such as those resulting in gas gangrene of 
the liver, it may be necessary to remove the liver 
and sustain the patient with a temporary veno-
venous bypass or portacaval shunt in 
expectation that another donor can be found 
quickly. 222 
Hepatic artery strictures without thrombosis 
cause ischemic graft injury. Percutaneous 
transluminal angioplasty has been used to 
manage these lesions.223• 224 Direct surgical 
repair is difficult and rarely successful. 
Aneurysms of the hepatic artery are rare 
after transplantation and are usually anastomotic 
220 Yanakga K, Lebeau G, Marsh JW, et al. Hepatic 
artery reconstruction for hepatic artery thrombosis 
after orthotopic liver transplantation. Arch Surg 
125:628-31, 1990. 
221 Hidalgo EG, Abad J, Canterero JM, et al. High 
dose intra-arterial urokinase for the treatment of of 
hepatic artery thrombosis in liver transplantation. 
Hepatogastroenterology 36:529-32, 1989. 
222 Shaked A, McDiarmid SV, Harrison RE, 
Gelebert H:, Colonna JO, Busuttil RW. Hepatic 
artery thrombosis resulting in gas gangrene of the 
transplanted liver. Surgery 111:462-5, 1992. 
223 Abad J, Hidlago EG, Cantarero J, Parga G, et al. 
Hepatic artery anastomotic stenosis after 
transplantation: treatment with percutaneous 
transluminal angioplasty. Radiology .171:661-2, 
1989. 
224 Castaneda F, So S, Hunter DW, et al. Reversible 
hepatic transplant ischemia: case. report and review 
of literature. Cardiovasc Intervent Radiol 13:88-90, 
1990. 
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pseudoaneurysms caused by a combination. of 
technical flaws and infection. The diagnOSis in 
many cases can be made by CT scan or duplex 
sonography, but angiography is required for a 
definitive diagnosis.225 These lesions may 
present with intra-abdominal or gastrointestinal 
bleeding, but typically they are asymptomatic 
and are detected on screening examinations 
conducted for other purposes. Management 
options include embolization, excision with 
ligation, direct repair or reconstruction with an 
arterial conduit, and retransplantation. Patients 
who present with infected pseudoaneurysms 
from biliary leakage are more likely to require 
retransplantation for successful management 
than patients who present with bleeding without 
associated bile leakage.226 
An important consideration in. the 
differential diagnosis of sudden hemorrhage is 
splenic artery aneurysm, which has been shown 
to have a significant propensity to rupture after 
liver transpl antation. 227. 228 Preoperati ve 
225 Tobben PI, Zajko ABm pumki~ JH, et al. 
Pseudoaneurysms complicating organ 
transplantation: roles of CT, duplex sonography, and 
angiography. Radiology 169:65-70, 1988. 
226 Madriaga J, tzakis A, Zajko A, et al. Hepatic 
artery pseudoaneurysm ligation after orthotopic liver 
transplantation. Transplantation 54:824-8, 1992. 
227 Ayalon A, Weisner RH, Perkins JD, Tominaga 
S, Hayes D, Krom RA. Spienic artery aneurysms in 
liver transplant patients. Transplantation 4R:PUS~9I 
1988. 
228 Breams JJ, Hiatt JR, Klein AS, Colonna JO, 
Busuttil RW. Splenic artery aneurysm rupture 
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imaging studies should be examined and the 
superior aspect of the pancreas should be 
palpated during surgery to look for these 
lesions, which should be ligated if identified. 
Portal vein. Postoperati ve portal vein 
thrombosis or stenosis are infrequent 
complications that can present with acute 
hepatic necrosis, esophageal variceal 
hemorrhage, or refractory ascites. In some 
patients, mild disturbances of liver function tests 
and prothrombin time and enlarging, but 
nonbleeding, esophageal varices, may be the 
presenting signs.229 
As with arterial thrombosis, management 
depends upon presentation. If liver function is 
well preserved, retransplantation may be 
avoided in favor of nonoperative therapy, direct 
repair, or conventional management of the 
complications of portal hypertension. 
Percutaneous transhepatic portal vein 
angioplasty with intraluminal stenting has been 
used to treat portal vein stenosis.230 Splenorenal 
shunts have been used to manage patients whose 
following orthotopic liver transplantation. 
Transplantation 45:1136-7, 1988. 
229 Burke GW, Ascher NL, Hunter D, Najarian JS. 
Orthotopic liver transplantation: nonoperative 
management of early acute portal vein thrombosis. 
Surgery 104:924-8, 1988. 
230 Olcott EW, Ring EJ, Roberts JP, Ascher NL, 
Lake JR, Gordon' RL. Percutaneous portal vein 
angioplasty and stent placement after liver 




principal presentation is esophageal variceal 
hemorrhage.231,232 
Inferior vena cava. Obstruction of the 
venous outflow from the graft at' the 
suprahepatic caval anastomosis is rare, but can 
occur with end to end anastomosis of the hepatic 
veins in reduced size liver grafts.233 It presents 
as a Budd-Chiari syndrome and should be 
considered in any patient with an enlarged graft 
and persistent ascites. Liver biopsy may show 
persistent centrilobular congestion. Doppler 
ultrasound examination of the hepatic veins 
shows loss of normal hepatic vein and inferior 
vena cava periodicity and may show distension 
of the hepatic veins and vena cava with high 
velocity jetstreaming at the anastomotic site.234 
However, perioperative ischemia and acute 
rejection may also produce abrupt dampening of 
231 Rouch DA, Emond IC, Ferrari M, Yousefzadeh 
D, Whitington P, Broelsch CE. The successful 
management of portal vein thrombosis after hepatic 
transplantation with a splenorenal shunt. Surg 
Gynecol Obstet 166:311-6, 1988. 
232 Marino IR, Esquivel CO, Zajko AB, et al. Distal 
splenorenal shunt for portal vein thrombosis after 
liver transplantation. Am I Gastroenterol 84:67-70, 
1989. 
233 Emond JC, Heffron TG, Whitington PF, 
Broelsch C. Reconstruction of the hepatic vein in 
reduced size liver transplantation. Surg Gynecol 
Obstet 176:11-17, 1993. 
234 Rossi AR, Pozniak MA, Zarvan NP. Upper 
inferior vena caval anastomotic stenosis in liver 
transplant recipients: Doppler US diagnosis. 
Radiology 187:387-9, 1993. 
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the pulsatile waveform present in the hepatic 
veins.235. 236 
Biliary tract 
In the most recent analysis of technical 
complications after liver transplantation in 323 
patients at the University of Pittsburgh, biliary 
obstruction or leakage occurred in 18% of 
patients.206 In a series of 226 patients at the 
University of Nebraska, the incidence of biliary 
tract complications was similar (19.1%) and 
necessitated reoperation in 13.4%.237 
In the Pittsburgh series, the incidence of 
obstruction after duct -to-duct reconstruction 
(18%) was significantly higher than the 
incidence after reconstruction by Roux-en-Y 
choledochojejunostomy (3%). However, the 
incidence of biliary leakage was higher after 
choledochojejunostomy (9% vs. 2%). In both 
the Omaha and Pittsburgh experience, 
complications after choledochojejunostomy 
tended to occur earlier and require more 
235 Coulden RA, Britton PD, Farman P, Nobel JG, 
Wight 00. Preliminary report: hepatic vein Doppler 
in the early diagnosis of acute liver transplant 
rejection. Lancet 336:273-5, 1990. 
236 Britton PD; Lomas DJ, Coulden RA, Farman P, 
Revell S. Tbe role of bepatic vein Doppler in 
diagnosing acute rejection following paediatric liver 
transplantation. Clin RadioI45:228-32, 1992. 
237 Stratta RJ, Wood RP, Langnas AN, et al. 
Diagnosis and treatment of biliary tract 
complications after orthotopic liver transplantation. 
Surgery 106:675-83, 1989. 
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operative intervention than complications after 
duct -to-duct reconstruction. 
Both radionucleid imaging and sonography 
have been useful in the diagnosis of biliary tract 
complications, but contrast cholangiography 
remains the most reliable diagnostic method. 238. 
239 Doppler ultrasound screening to evaluate the 
status of the hepatic artery and portal vein, 
however, is an important component of the 
evaluation of any biliary fistula or stricture. 
The T-tube exit site is the most common 
place that biliary leaks occur after duct-to:..duct 
reconstruction. Small leaks discovered in an 
asymptomatic patient on routine contrast studies 
usually do not require treatment. Many minor 
symptomatic leaks, such as those occurring after 
T-tube removal, can be managed expectantly or 
by endoscopic placement of a nasobiliary 
stent.240 Few patients require laparotomy for 
suture repair of the T-tube exit site. 
238 Anselmi M, Lancberg S, Deakin M, et al. 
Assessment of biliary tract after liver 
transplantation: T-tube cholangiograpby or IODIDA 
scanning. Br J Surg 77:1233-7, .1990. 
239 Zemel G, Zajko AB, Skolnick ML, Bron KM. 
The role of sonograpby and transhepatic 
cholangiography in the diagnosis of biliary tract 
complications after liver transplantation. Am J 
RoentgenoI151:943-6, 1988. 
240 Ostroff JW, Roberts JP, Gordon RL, Ring EJ, 
Ascher NL. The management of T-tube leaks in 
orthotopic liver transplant recipients with 
endoscopically placed nasobiliary catheters. 
Transplantation 49:922-4, 1990. 
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Anastomotic leaks are more serious and 
usually require operative intervention. The 
status of the hepatic artery must be determined 
before repair is attempted. Direct repair of a leak 
from a duct-to-duct anastomosis is hazardous; it 
is usually prudent to convert the reconstruction 
to a Roux-en-Y choledochojejunostomy. 
Leakage from a choledochojejunostomy is 
usually associated with intestinal soilage which 
may prohibit immediate repair. A fresh 
anastomosis to a segment of healthy bowel 
should be performed when feasible. High 
anastomosis of jejunal mucosa to the hepatic 
capsule and parenchyma (intrahepatic 
cholangiojejunost~myF has been used 
successfully in patients with infection and 
destruction of the extrahepatic biliary tree.241 
Numerous studies have demonstrated an 
association between the development of biliary 
strictures after liver transplantation and graft 
ischemic injury. Risk factors for the 
development of biliary strictures include 
prolonged graft preservation time in either Euro-
Collins or UW solutions, high dose pressor 
support of the donor prior to procurement of the 
liver, ABO incompatibility between the donor 
241 Langnas AN, Stratta RJ, Wood RP, Ozaki CF, 
Bynon JS, Shaw BW. The role of intrahepatic 
cholangiojejunostomy in liver transplant recipients 
after extensive destruction of the extrahepaticbiliary 
system. Surgery 112:712-7, 1992. 
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and the recipient, and occult hepatic artery 
thrombosis.242-245 
Percutaneous biliary dilatation of biliary 
strictures has a reported success rate ranging 
from 40% to 90%.246 The Mayo Clinic reports 
achieving long term patency in 88% of patients 
treated with biliary stents and repeated biliary 
dilatations. However, one year graft survival in 
patients with ischemic biliary strictures is 69% 
compared to 88% in patients without such 
complications.247 
Several studies have reported an increased 
incidence of non-anastomotic biliary strictures 
242 Li S, Stratta RJ, Langnas AN, Wood RP, Marujo 
W, Shaw BW Jr. Diffuse biliary tract injury after 
orthotopic liver transplantation. Am J Surg 164:536-
40, 1992. 
243 Colonna JO, Shaked A, Gomes AS, et al. Biliary 
strictures complicating liver transplantation. 
Incidence, pathogenesis, and outcome. Ann Surg 
216:344-50, 1992. 
244 Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. 
Ischemic type biliary complications after orthotopic 
liver transplantation. Hepatology 16:49-53, 1992. 
245 Sankary HN, McChesney L, Hart M, Foster P, 
Willi:uns J. Identification of donor and recipient risk 
factors associated with non anastomotic biliary 
strictures in human hepatic allografts. Transplant 
Proc 25:1964-67,1993. 
246 Morrison MC, Lee MJ, Sani S, Brink JA; 
Mueller PRo Percutaneous balloon dilatauon of 
benign biliary strictures. Radiol Clin North Am 
28:1191-201,1990. 
247 Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. 
Diagnostic features and clinical outcome of 
ischemic-type biliary complications ·after liver 
transplantation. Hepatology 17:605-9, 1993. 
Orthotopic Liver Transplantation· 
in patients who received a transplant for primary 
sclerosing cholangitis (pSC).245.248 In a review 
of the cholangiograms obtained in 643 recipients 
of 687 liver grafts at the University of 
Pittsburgh, intrahepatic biliary strictures were 
identified in 105 (15%) allografts, anastomotic 
strictures in 105 allografts(15%), and non-
anastomotic extrahepatic biliary strictures in 17 
allografts (2%). The incidence of intrahepatic 
biliary strictures was significantly higher in 
patients who received a transplant for PSC 
(27%) compared to those who underwent 
transplantation for other reasons (13%). Non-
anastomotic extrahepatic biliary strictures were 
also more common in the PSC group (6% versus 
2%). Whether the increased incidence of non-
anastomotic structures after liver transplantation 
for PSC is a manifestation of the original 
disease, or a complication more likely to occur 
in patients with a choledochojejunostomy, is not 
known. So far, there has been no demonstrated 
increased incidence of non-anastomotic 
strictures in patients reconstructed with 
choledochojejunostomy after liver 
transplantation for diseases other than PSc. 
A "biliary cast syndrome" with the 
accumulation and concretion of sludge in the 
bi1i~ tree in the absence of an anastomotic 
stricture is a reported complication after liver 
248 Sheng R, Zajko AB, Campbell WL, Abu-Elmagd 
K. Biliary stJ:ictures in hepatic transplants: 
prevalence and types in patients with primary 




transplantation. A combination of medical 
therapy with choliuretic drugs, interventional 
radiology to manage intrahepatic strictures, and 
surgical revision of the biliary reconstruction 
have been used to avoid retransplantation in 
such cases.249 
A modest dilatation of the biliary tree is 
commonly seen after liver transplantation and is 
of no clinical significance.25o A functional 
obstruction of the biliary tree with progressive 
dilatation of the extrahepatic and intrahepatic 
bile ducts in the absence of any strictures may 
occur after duct-to-duct reconstruction. This 
"ampuIlary dysfunction syndrome" may be the 
result of denervation of the ampulla of Vater 
during the hilar dissection necessary to remove 
the native liver and expose the hepatic artery. 
Although it has been rarely discussed in the 
literature, this syndrome is well known to liver 
transplant surgeons. It usual1y requires 
endoscopic papiIIotomy or surgical revision to a 
choledochojejunostomy. 
249 Chen CL, Wang KL, Chuang JH, Lin IN, Chu 
MF, Chang CH. Biliary ·sludge-cast formation 
following liver transplantation. 
Hepatogastroenterology 35:22-4, 1988. 
250 Campbell WL, Foster RG, Miller JW, Lecky 
JW, Zajko AB, Lee KY. Changes in 'extrahepatic 
bile duct caliber in liver recipients without evidence 
of biliary obstruction. Am J Roentgenol 158:997-
1000,1992 .. 
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Gastrointestinal and other 
systemic complications 
Intestinal obstruction is an infrequent 
complication after liver transplantation, since 
most adhesions are confined to the supracolic 
portion of the abdomen. If a Roux-en-Y limb 
has been used for biliary reconstruction, small 
bowel may herniate under the mesentery of the 
Roux-Y limb if it has not been tacked to the 
peritoneum. Pseudo-obstruction of the colon 
also occurs, but it is less common than after 
kidney transplantation. 
The jejunojejunostomy performed to 
construct a Roux-en-Y limb is often the site of 
an intestinal fistula or of occult gastrointestinal 
bleeding when these complications occur after 
liver transplantation. Anastomotic leaks have 
been more frequent in children. An enteric leak 
or fistula should be suspected whenever there is 
evidence of intra-abdominal polymicrobial or 
candida infection. Late bowel perforations are 
most often caused by diverticulitis, appendicitis, 
cytomegalovirus enteritis, or 
lymphoproliferative lesions. 
Esophageal, gastric, intestinal, colonic and 
rectal ulcerations, with or without hemorrhage, 
may result from opportunistic infection as seen 
in cytomegalovirus gastroenteritis and colitis 
and Clostridium· difficile colitis. Management 
includes appropriate antibiotic therapy 
(ganciclovir, metronidazole), blood replacement, 
and reduction in immunosuppression. In 




Ascites often persists for weeks to several 
months after transplantation and should be 
managed in the usual manner with salt 
restriction, spironolactone, and loop diuretics. 
Large volume paracentesis with colloid 
replacement (25% salt poor albumin) is used for 
severe cases. If the portal vein is patent and 
venous outflow is unobstructed, the ascites will 
eventually resolve. Peritoneovenous shunting is 
rarely indicated. Late recurrence of ascites 
suggests recurrent liver disease, including 
chronic rejection, hepatitis, or recurrent primary 
disease. 
The etiology of pancreatitis after liver 
transplantation is not certain and often is 
multifactorial. Manipulation of the gland during 
dissection, congestion of the pancreas during the 
anhepatic phase of surgery, ischemic damage 
from ligation of the gastroduodenal artery, and 
use of high dose steroids for induction 
immunosuppression are possible contributing 
factors. A mild amylasemia is common early 
after liver transplantation and usually resolves in 
a few days. Persistent amylasemia and elevated 
serum lipase with edema of the pancreas on CT 
scan or ultrasound are more ominous and often 
herald pancreatic abscess, pseudocyst or 
hemorrhagic pancreatitis. Significant clinical 
pancreatitis is most common after liver 
transplantation in patients with active viral 
hepatitis at the time of transplantation, 
especially if acute hepatitis B is present.251 The 
251 Alexander J, Demetris AJ, Gavaler JS, Makowka 
L, Stanl ill, Van Thiel DH. Pancreatitis following 
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morbidity and mortality of major pancreatic 
complications after liver transplantation are 
high. 
There is a significant incidence of hepatitis 
associated aplastic anemia developing one to 
seven weeks after liver transplantation 
performed for acute non-A, non-B hepatitis. 
Mortality has been high, but marrow recovery 
has occurred in some patients followed for more 
than a year.252 A recent study suggests that the 
aplastic anemia in these cases is due to a non-A, 
non-B, non-C hepatitis virus.253 
Infection 
Decreased reliance on azathioprine and 
, 
steroids has made bacterial infection less of an 
problem in organ transplantation, but infections, 
especially opportunistic viral and fungal 
infections, are associated still with much of the 
morbidity and mortality after liver 
liver transplantation. Transplantation 45: 1062-6, 
1988. 
252 Tzakis AG, Arditis M, Whitington PF, et al. 
Aplastic anemia complicating orthotopic liver 
transplantation for non-A, non-B hepatitis. N Engl J 
~ed 319:393-6, 1988. 
253 Hibbs' JR, Frickhofen N, Rosenfeld SJ, et aI. 
Aplastic anemia and viral hepatitis. Non-A, non-B, 




transplantation.254-256257 Over 80% of liver 
recipients have one or more episodes of 
infection and two-thirds of these infections are 
serious. Seventy percent Qf infections occur in 
the first 60 days after transplantation. In the first 
month, bacterial and fungal infections 
predominate. Bacterial sepsis is often associated 
with ischemic graft injury, severe rejection, or 
cholangitis. After the first month, viral 
infections are more common. In the reported 
experience from the University of Pittsburgh, 
the overall incidence of viral infection was 59% 
for cytomegalovirus (CMV), 35% for herpes 
simplex (HSV), 25% for Epstein-Barr virus 
(EBV), and 7% for varicella-zoster (VZV).258 
254 Kusne S, Dummer J, Singh N, et aI. Infections 
after liver transplantation. An anaIysis of 101 
consecutive cases. Medicine 67:132-43, 1988. 
255 Markin RS, Stratta RJ, Woods GL. Infection 
after liver transplantation. Am J Surg 14:64-78, 
1990. 
256 Paya CV, Hennans PE, Washington JA, et aI. 
Incidence, distribution, and outcome of episodes of 
infection in 100 orthotopic liver transplantations. 
Mayo Clin Proc 64:555-64,1989. 
257 Barkholt L, Ericzon BG, Tollemar J, et aI. 
Infections in human liver recipients: different 
patterns early and late after transplantation. 
Transplant Int 6:77-84, 1993. 
258 Singb N, Dummer JS, Kusne S, et aI. Infections 
with cytomegalovirus and other berpes viruses in 
121 liver transplant recipients: transmission by 
donated organ and the effect of OKT3 antibodies. J 
Infect Dis 158: 124-31, 1988. 
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Bacterial pneumonia occurs in 17% of liver 
recipients.259 In the first three months after 
transplantation gram-negative bacilli and 
Staphylococcus aureus have predominated. 
Prophylaxis with single strength trimethoprim-
sulfamethoxasole has proven to be highly 
effective in preventing Pnemocystis carinii 
pneumonia, once a major cause of mortality 
after solid organ transplantation. It has also 
made Legionella pneumonia a rarity. 'This 
prophylaxis should be continued indefinitely, 
since pneuomocystis pneumonia can occur if 
patients are withdrawn from antibiotic 
prophylaxis even years after transplantation. For 
patients with an allergy to sulfa drugs, monthly 
inhalation therapy with Pentamidine is also 
effective.26o Bronchoalveolar lavage is quite 
helpful in the early diagnosis of pulmonary 
infections in immunosuppressed patients. 
Cytomegalovirus (CMV) infections are the 
most common viral infections encountered in 
liver transplant recipients and can present with 
esophagitis, gastroenteritis, proctocolitis, 
hepatitis, pneumonitis, or retinitis. 
Cytomegalovirus infections may also involve 
the skin and be mistaken for herpes simplex 
259 Mermel LA, Maki DG. Bacterial pneumonia in 
solid· organ transplantation .. Semin ·Respir Infect 
5: 10-29, 1990. 
260 Hirscbel B, Lazzarin A, Cbopard P, et al. A 
controlled study of inhaled pentamidine for primary 
prevention of Pneumocystis carinii pneumonia. N 
Engl J Med 324:1079-83, 1991. 
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infections.26l . 262 Seronegative recipients of 
organs from seropositive recipients are at the 
highest risk, but patients treated with heavy 
immunosuppression, especially antilymphocyte 
therapy, or requiring retransplantation, are also 
at increased risk.263-266 
Prophylaxis with CMV immune globulin or 
acyclovir has been advocated for high risk 
patients. A recent meta-analysis of 18 clinical 
trials of immune globulin prophylaxis in bone 
marrow and solid organ transplant recipients 
confirmed a beneficial effect of either 
261 Lee JY. Cytomegalovirus infection involving the 
skin in immunocompromised bosts, a 
clinicopathological study. Am J Clin Pathol 91:96-
100,1989. 
262 Patterson JW, Broeker Ail, Kornstein MJ, Mills 
As. Cutaneous cytomegalovirus infection in a liver 
transplant recipient. Diagnosis by in situ DNA 
hybridization. Am J Dermatopathol 10:524-30, 
1988. 
263Gorensek MJ, Carey WD, Vogt D, Goormastic 
M. A multivariate analysis of risk factors for 
cytomegalovirus infection in liver transplant 
recipients. Gastroenterology 98: 1326-32, 1990. 
264 Hooks MA, Perlino CA, Henderson 1M, Millikan 
WJ, Kutner MH. Prevalence of invasive 
cytomegalovirus disease with administration of 
muromonab CD-3 in patients undergoing orthotopic 
liver transplantation. Ann Pbaramcother 26:617-20, 
1992. 
265 Pillay D, Cbarrnan H, Burroughs AK, Smith M, 
RoUes K, Griffiths PD. Surveillance for CMV 
infection in orthotopic liver transplant recipieQts. 
Transplantation 53: 1261-5, 1992. . 
266 Stratta R, Scheefer MS, Mirkin RS, et al. 
Clinical patterns of cytomegalovirus disease' after 
liver transplantation. Arch Surg 124:1443-9; 1989. 
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hyperimmune or the less expensive polyvalent 
immune globulin.267 High dose acyclovir 
therapy has shown efficacy for CMV 
prophylaxis in a randomized placebo-contrOlled 
trial in renal allograft recipients.268 A more 
recent trial using a similar protocol showed a 
reduction in the incidence of CMV infection and 
disease in seropositive recipients, but had no 
effect on the incidence or mortality of CMV 
pneumonia, and had no demonstrable benefit for 
seronegative recipients.269 
Bismuth has reported a significant decrease 
in the incidence of CMV infection and disease, 
especially in CMV seropositive recipients, with 
high dose acyclovir given for the first three 
months after liver transplantation. 270 The 
Omaha group has shown a significant reducti9n 
in the incidence of herpetic and Epstein-Barr 
virus infections, but no difference in the 
267 Glowaki LS, Smail FM. Meta-analysis of 
immune globulin prophylaxis in transplant recipients 
for the prevention of symptomatic cytomegalovirus 
disease. Transplant Peoc 25:1408-10, 1993. 
268 Balfour llli, Chace BA, Stapelton IT, Simmons 
RL, Fryd DS. A randomized placebo-controlled trial 
of oral acyclovir for the prevention of 
cytomegalovirus disease in recipients of renal 
allografts. N Engl J Med 320: 1381-7, 1989. 
269 Legendre C, Ducloux D, Ferroni A, et al. 
Acyclovir in preventing cytomeglaovirus infection 
in kidney transplant recipients. Transplant Proc 
25:1431-33, 1993. 
270 Saliba F, Eyraud D, Samuel MF, et al. 
Randomized contrQIled trial of acyclovir for the 
prevention of cytomegalovirus infection and disease 




incidence of cytomegalovirus infections, in a 
randomized prospective trial of acyclovir and 
immune globulin prophylaxiS in liver transplant 
reCipients who had received OKT3.271 
Since the upper gastrointestinal tract and 
the allograft liver are the organ systems· most 
commonly involved with significant CMV 
disease, biopsy specimens obtained from these 
tissues are especially helpful in establishing a 
diagnosis. In studies comparing conventional 
light microscopy, immunoperoxidase staining 
with monoclonal or polyclonal antibody, in situ 
DNA hydridization, and inoculation of cell 
cultures,immunostaining with monoclonal 
antibody has been shown to be the most 
expedient and the most reliable method for early 
detection of CMV infection in tissue 
specimens.272-274 In situ DNA hybridi2ation 
271 Stratta RJ, Schaefer MS, Cushing KA, et al. A 
randomized prospective trial of acyclovir and 
immune globulin prophylaxis in liver transplant 
recipients receiving OKT3 therapy. Arch Surg 
127:55-63, 1992. 
272 Paya CV, Holley hb~ Wiesner RH, et al. Early 
diagnOSis of.. cytomegalovirus hepatitis in liver 
transplant recipients: role of immunostaining, DNA 
hybridization and culture of hepatic tissue. 
Hepatology 12: 119-26, 1990. 
273 Theise ND, Conn M, Tbung SN. Localization of 
cytomegalovirus antigens in liver allografts over 
time. Hum PathoI24:103-8, 1993. 
274 Rabah R, Jaffe R. Early detection of 
cytomegalovirus in the allograft liver biopsy: a 
comparison of methods. Pediatr Pathol 7:5549-56, 
1987. . 
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shows high sensitivity, but lacks specificity.275 
A significant number of patients with CMV 
detected by polymerase chain reaction never 
develop clinically significant disease.276 
The treatment of choice for 
cytomegalovirus infection is intravenous 
ganciclovir, 9-(1 ,3-dihydroxy-2-propoxymethyl) 
guanine.277-280 Usually a minimum of 14 days 
of therapy is required. Foscarnet is an alternative 
drug for the exceptional patient whose infection 
is resistant to ganciclovir. 
275 Masib AS. Linder J. Shaw BW. Wood RP. Rapid 
identification of cytomegalovirus in liver allograft 
biopsies by in situ hybridization. Am J Surg Pathol 
12:362-7.1988. 
276 Delgado R. Lumreras C. Alba C. et al. Low 
predictive value of polymerase chain reaction for 
diagnosis of cytomegalovirus disease in liver 
transplant recipients. J Clin Microbiol 30: 1876-8. 
1992. 
277 Harbison MA. De Girolami PC. Jenkins RL. 
Hammer SM. Ganciclovir therapy of severe 
cytomegalovirus infection in solid-organ transplant 
recipients. Transplantation 46:82-8. 1988. 
278 Paya CV, Hermans OE, Smith IF, et al. Efficacy 
of ganciclovir in liver and kidney transplant 
recipients with severe cytomegalovirus infection. 
Transplantation 46:229-34. 1988 . 
. 
279 DAlessandro AM, Pirsch JD. Stratta RJ. 
Sollinger HW. Kalayoglu M. Belzer FO. Successful 
treatment of severe cytomeglaovirus infections with 
ganciclovir and CMV immune globulin in liver 
transplant recipients. Transplant Proc 21 :3560-1, 
1989. 
280 deHemptine B. Lamy ME. Salizzoni M, et al. 
Successful treatment of cytomegalovirus disease 
with 9-(1,3-dibydroxy-2-propoxymetllyl guanine). 
Transplant Proc 20:652-5. 1988. 
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Herpes simplex infections in transplant 
recipients are usually oral or genital 
reactivations. but HSV can cause a severe 
hepatitis or pneumonitis.258, 281 HSV 
reactivation infections are more common in 
patients treated with antilymphocyte therapy. 
Acyclovir is effective treatment and low dose 
prophylaxis with acyclovir is recommended for 
at least six months after transplantation. 
Disseminated varicella-zoster infections in 
immunosuppressed patients require high dose 
therapy with acyclovir and have a high 
morbidity and mortality. Patients seronegative 
for varicel1a-zoster should receive a course of 
VZV immune globulin (VZIG) within 72 hours 
of exposure to an actively infected individual. In 
high risk exposures. such as a family member 
with chicken pox. it is also prudent to give 
VZIG to a seropositive patient and to administer 
acyclovir to seronegative patients. since clinical 
disease has been reported in susceptible 
individuals even after a course of VZIG.282 
Epstein-Barr virus is a ubiquitous DNA 
virus. EBV infections after liver transplantation 
are discussed below with post-transplant 
lymphoproliferative disorders. 
281 Kusne S, Schwartz M. Breinig MK, et al. Herpes 
simplex virus infections after solid organ 
transplantation. J Infect Disease 163:1001-,1991. 
282 McGregor RS. Zitelli BJ, Urbach AH, et al. 
Varicella in orthotopic liver transplant recipients. 
Pediatrics 83:256-61. 1989. 
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The most common fungal pathogens 
encountered in immunosuppressed patients are 
candida species. These are most often non-
invasive overgrowths in the oropharyngeal, 
esophageal, and vaginal cavities and respond to 
topical therapy. Invasive candidiasis requires 
systemic therapy with amphotericin B or 
fluconazole. Although preoperative selective 
decontamination of the gut has been shown to 
reduce the incidence of gram negative bacterial 
and candida infections, there are practical 
limitations to its use and it has not been shown 
to affect patient mortality.283, 284 
Aspergillus infections may present in the 
upper and lower respiratory tracts, skin, soft 
tissues, or central nervous system. A diffuse 
pneumonia with patchy infiltrates is a common 
presentation. Blood vessel invasion occurs early 
and may lead to insidious development of brain 
abscesses which are difficult to cure. A long 
course of systemic antifungal therapy is 
required. 
Cryptococcal infection should be suspected 
in any immunocompromised patient with 
headache or meningismus. Appropriate tests for 
283 Weisner RH, Hennans PE, Rekela J, et al. 
Selective bowel decontamination to decrease gram-
negative aerobic bacterial and candida colonization 
and prevent infection after orthotopic liver 
transplantation. Transplantation 45:570-4, 1988. 
284 Badger IL, Crosby HA, Kong KL, et al. Is 
selective decontamination of the digestive tract 
beneficial in liver transplant patients? Interim results 
of a prospective randomized trial. Transplant Proc 
23:1460-1, 1991. . 
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cryptococcal antigens, and India ink stain and 
fungal cultures of spinal fluid should be 
obtained. Invasive infections with Mucor or 
Rizopus species are rare, but do produce lethal 
CNS and soft tissue infections. Treatment 
includes reduction of immunosuppression, 
excision of localized lesions, and a long course 
of systemic antifungal therapy. 
De novo malignancies after liver 
transplantation 
Approximately 6% of organ transplant 
reCipients develop de novo neoplasms. Mortality 
from these cancers is only 1%. The cancers most 
common in organ transplant recipients include 
skin and lip cancers (especially squamous cell 
cancers), non-Hodgkin's lymphomas, Kaposi's 
sarcoma, vulvar and perineal carcinomas, and 
in-situ uterine cervical carcinomas.285 
Post-transplant Iymphoproliferative 
disorders (PTLD) 
Epstein-Barr virus (EBV) infection is 
common in organ transplant reCipients. In a 
review of 51 consecutive pediatric liver 
recipients at the University of Pittsburgh, the 
incidence of primary and reactivation EBV 
infection was 68% and 48% respectively, rates 
similar to those seen in adults.286 Most clinical 
285 Penn I. Occurrence of cancers in 
immunosuppressed organ transplant recipients. Clin 
Transplantation 4:53-62, 1990. 
286 Breinig MK, Zitelli B, Starzl TE, Ho M. 
Epstein-Barr virus, cytomegalovirus, and other viral 
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infections with EBV result in a systemic viral 
syndrome resembling infectious mononucleosis 
or present in atypical form with jaw pain, 
arthralgias, joint space effusions, diarrhea, 
encephalitis, pneumonitis, mediastinal 
lymphadenopathy, or ascites. Findings in the 
liver graft may include a mixed mononuclear 
portal and sinusoidal infiltrate with atypical 
large, noncleaved cells and immunoblasts, but 
with minimal damage to bile ducts, and an 
associated lobular hepatitis.287 
EBV has been associated Clinically with 
two B-cell malignancies, Burkitt's lymphoma 
and B-cell lymphomas in immunosuppressed 
hosts. Among the non-Hodgkin's lymphomas 
occurring after organ transplantation, 86% are of 
B-cell origin, 14% are of T-cell origin, and less 
than 1 % are null cell in origin. Extranodal 
involvement is common (69%). Involvement of 
the central nervous system, which is rare in the 
general population, is usually confined to the 
brain and is found in 28% of affected 
patients.285 
The reported incidence of 
lymphoproliferative disorders after liver 
transplantation is 1.7% to 2.5%.288-290 The B-
infections in children after liver transplantation. J 
Infect Dis 156:273-9, 1987_ 
287 Randhawa PS, Markin RS, Starzl TE, Demetris 
AJ. Epstein-Barr virus-associated syndromes in 
immunosuppressed liver transplant recipients. Am J 
Surg Path 14:538-47, 1990. 
OU~ Nalesnik MA, Makowka L, Starzl TE. The 
diagnosis and treatment of posttransplant 
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cell lesions range from a polymorphic B-cell 
hyperplasia to a variety of frank polyclonal or 
monoclonal B-cell lymphomas including 
immunoblastic tumors and plasmacytomas.291 
The liver allograft is involved in over one-
third of cases, but the tonsils, gastrointestinal 
tract, and kidneys are also frequently affected.292 
Localized lesions in the gastrointestinal tract 
may obstruct or perforate and when found need 
to be excised. Lesions in the oropharynx, 
especially in children, may produce respiratory 
obstruction and require surgical excision.293 
Biopsy of involved tonsils can be hazardous. 
Lesions occurring early after transplantation 
(within 3 months) are most common in patients 
with early, aggressive rejection treated with 
lymphoproliferative disorders. Curr Prob Surg 
25:367-42, 1988. 
289McAlister V, Grant D, Roy A, Vilmaz Z, Ghent 
C, Wall W. Posttransplant lymphoproliferative 
disorders in liver recipients treated with OKT3 or 
ALG induction immunosuppression. Transplant Proc 
25: 1400-1, .1993. 
290 Levy M, Bachman B, Husberg B, et al. De novo 
maligancy following liver transplantaiton: a single-
center study. Transplant Proc 25:1397-1399,1993. 
291 Ferry JA, Jacobson JO, Conti D, Delmonico F, 
Harris NL. Lymphoproliferative. disorders and 
hematologic malignancies . following organ 
transplantation. Mod Pathol 2:583-92, 1989 .. 
292 Cohen n. Epstein-Barr virus lymphoproliferaUve 
disease associated with acquired immunodeficiency. 
Medicine 70:137-60, 1991. 
293Sculerati N, Arriaga M. Otolaryngologic 
management of posttrarisplant lymphoproliferative 
disease in children. Ann Otol Rhinol Laryngol 
99:445-50, 1990. 
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heavy immunosuppression, especially 
monoclonal or polyclonal antibody therapy. 
Patients who receive multiple courses of anti-
lymphocyte antibody therapy for rejection are at 
highest risk for a P1LD.289, 294 
Treatment consists of withdrawal of 
immunosuppression, administration of high 
dose acyclovir, and resection of troublesome 
localized lesions. When allograft graft rejection 
occurs, it is anticipated that the immune system 
will have recovered enough to control the 
lymphoproliferati ve process and that 
immunosuppression can be cautiously resumed. 
Survival has been. hi.ghest in patients with the 
least number of organ systems involved and 
with polyclonal rather than monoclonal 
lesions.292 Aggressive malignant lesions which 
fail to respond' to reduction of 
immunosuppression may require treatment with 
systemic cheII).otherapy or radiotherapy, but 
mortality for these lesions is high. 
Genetic probing techniques have been used 
in an effort to identify patients. at greatest risk of 
developing EBV-related lymphoproliferative 
lesions and to assist in making a distinction 
between the lymphocytic infiltrates seen in 
allograft rejection and the lymphoid hyperplasia 
seen in EBV-related syndromes. Tissue 
specimens from transplant recipients with 
rnKa~ and from those without PTI..D but with a 
294 Solomon H,. Gonwa T A, Mor E, et aI. OKT3 
rescue for steroid-resistant rejection in adult liver 
p-allsplantation. Transplantation 55:87-91, 1993. 
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past history of EBV infection, have been 
compared using an in situ hybridization (ISH) 
technique with a synthetic oligonucleotide DNA 
probe from a tandem repeat region (NotI) that is 
abundantly transcribed during productive EBV 
infection. Tissue from all patients with P1LD 
examined by ISH showed nuclear staining for 
EBY in the lymphoid infiltrates. However, 
allograft biopsies from p~tients with acute 
cellular rejection and serological evidence of 
past EBY infection were negative. Thus, ISH 
with an appropriate probe can distinguish the 
atypical lymphoid infiltrate of EBV-associated 
PTI..D from the infiltrate of acute cellular 
rejection.295 
Also using INH with an oligonucleotide 
probe, Randhawa et al studied the tissue 
expression of a small RNA transcribed by the 
EBER-l gene during latent EBV infection to 
identify patients at risk of developing P1LD. 
EBER-! gene expression was studied in 
specimens from 24 liver recipients that had been 
obtained 2 days to 22 months before 
development of PTI..D. In 17 of the 23 patients, 
1 % to 40% of mononuclear cells were positive 
for EBER-l gene expression. In all 24 cases, 
EBER-l positive cells were identified in the 
lymphoproliferative lesions that ultimately 
developed. Only 2 of 20 control specimens 
295 Montone KT, Friedman H, Hodinka RL, Hocks 
DG, Kant lA, Tmaszewski JE. In situ hybridization 
for Epstein-Barr virus Not! repeats in posttransplant 
lymphoproliferative disorder. Mod Patbol 5:292-
302, 1992. 
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taken from patients with preservation injury of 
the graft, acute rejection, or viral hepatitis, but 
in whom PlLD had not developed within 9 to 
71 months after biopsy, showed EBER-l 
positive cells and these. were few in number. 
Thus, expression of the EBER-l gene may be a 
useful as a marker for the subsequent 
development of PlLD and for making 
appropriate adjustments in immunosuppressive 
therapy in patients who are found to be at 
risk.296 
Kaposi's sarcoma 
Kaposi's sarcoma, which has a negligible 
incidence in the general population, was an 
obscure tumor until its occurrence was 
associated with patients with acquired 
immunodeficiency syndrome. The incidence in 
organ transplant recipients is 6%. The lesions 
may be confined to the skin, conjunctiva, or 
oropharynx, but visceral involvement, usually of 
the lungs or gastrOintestinal tract, has been 
observed in 41 % of transplant patients. 285 The 
lesions may regress with reduction or temporary 
withdrawal of immunosuppression. The highest 
incidence in liver transplant recipients has been 
in males of Mediterranean origin. There is an 
association between Kaposi's sarcoma and 
CMV disease. The reported mortality of 
296 Randhawa PS, Jaffe R, Demetris AJ, et aI. 
Expression of Epstein-Barr virus-encoded small 
RNA (by the EBER-l gene) in liver specimens from 
transplant recipients with post-transplant 




Kaposi's sarcoma in liver transplant recipients is 
45%.297 
297 Bismuth H, Samuel D, Venancie G, menouaf G, 
Szekely AM. Development of Kaposi's sarcoma in 
liver transplant recipients: . characteristics, 
management, and outcome. Transplant Proc 
23:1438-39,1991. 
Liver Transplantation Survival 
SURVIVAL AFTER LIVER TRANSPLANTATION 
The number of organ transplantations 
performed in the United States has increased 
steadily for nearly 10 years (figure 13). Since 
cyclosporine became available for general use in 
the United States in 1984, patient and graft 
survival rates after liver transplantation have 
improved dramatically. Similar improvement in 
survival rates has been experienced in Europe 
also. By the end of the 1980s, nearly 9,100 liver 
transplantations had been performed at 133 
transplant centers on the two continents with 
one-year survival rates exceeding 75% and two-
year survival rates exceeding 65% for most 
indications.298 
Results in the United States 
A summary of the liver transplantation 
experience for the United States during the 
period from 1988-1990 was published by the 
UNOS Liver Transplant Registry in 1992.299 By 
1990 there were 75 liver transplant centers in 33 
states and the District of Columbia. Only 15 
centers performed 100 or more transplantations 
during the period from 1988 to 1990, and only 6 
298 Gordon RD and Bismuth R. Liver transplant 
registry report. Transplant Proc 23:58-60, 1991. 
299 Belle SR, Beringer K, Murphy J, et al' Liver 
Transplantation in the United States: 1988-1990. In: 
Clinical Transplants 1991. Teraski P, Cecka 1M, 
eds. Los Angeles,UCLA Tissue Typing Laboratory, 
13-29, 1992. 
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centers (7.5%) were performing more than 100 
transplantations per year. Twelve or less 
transplants were performed by 25 (31 %) of the 
centers. 
The indications for liver transplants 
performed between 1988 and 1990 are 
summarized in table 6. The most significant 
change has been the increase in the proportion 
of patients undergoing liver transplantation for 
alcoholic cirrhosis, which has grown from 9.1 % 
in 1988 to 17.8% in 1990. 
The age of liver transplant reCipients in the 
United States has been increasing with a median 
recipient age of 39 years in 1988, 42 years in 
1988, and 43 years in 1990. This has probably 
been encouraged by reports of successful 
transplantation of older recipients with survival 
rates comparable to younger adults. 300. 301 The 
national registry 6 month, I-year and 3-year 
survival rates, stratified by age groups, for liver 
transplant recipients in 1988-1990 are 
summarized in Table 11. 
Patient survival rates for the major 
indications for liver transplantation in adults and 
300 Starzl TE, Todo S, Gordon RD. Liver 
transplantation in older patients [letter]. N Engl 1 
Med 316:484, 1987. 
301 Stieber AC, Gordon RD, Todo S. Liver 
transplantation in patients over 60 years of age. 
Transplantation 51:271-84, 1991. 
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children are summarized in Tables 8 and 9. 
Among adults with primary biliary cirrhosis and 
sclerosing cholangitis, survival at 6-months after 
transplantation is high (86% and 88%, 
respectively) with high survival maintained out 
to three years of follow-up (78% and 79%, 
respectively). Survival rates after transplantation 
for chronic active hepatitis B and non-A, non-B 
are also good at 6 months (77% and 80%, 
respectively), but there is a greater attrition of 
patients, especially for hepatitis B, such that 
survival at 3-years is 54% and 68%, 
respectively. Survival of patients with alcoholic 
cirrhosis compares favorably to other patients 
with postnecrotic cirrhosis. The poorest long 
term survival is seen with patients receiving 
transplants for malignant neoplasms. 
In children, biliary atresia is by far the most 
common indication for liver transplantation, and 
accounts for more than 50% of the cases in most 
reported series. Survival for this condition at 6-
months is 82% with good survival being 
maintained out to 3 years (75%). 
Patient survival stratified according to the 
UNOS classification system for patient 
condition at the time of transplantation is 
summarized in Table 10. These results show a 
decreased survival as the level of hospital care 
required by the patient at the time of surgery 
increases. Oftly 61 % of patients on life support 
immediately prior to transplantation survive one 
year, compared to 75% of patients hospitalized, 
but not in an intensive care unit, and 81% of 
patients disabled at home. 
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Survival 
Finally, confirming of what has already 
been reported in single center studies, there is a 
significant patient and graft loss associated with 
transplantation across ABO blood groups. 
Results stratified according to donor and 
recipient ABO blood groups are presented in 
table 11. The poorer results with ABO 
mismatched grafts probably reflect both the 
biological disadvantages of crossing the ABO 
blood groups and, perhaps more importantly, the 
use of ABO mismatched grafts for more urgent 
patients. 
Results at the University of 
Pittsburgh 
The largest and oldest liver transplant 
program in the United States is located at the 
University of Pittsburgh. The results of liver 
transplantation at this center for the period from 
1984 to 1990 have been presented in detail 
elsewhere and will be summarized here. 302 
During the period from 1984 through 
September, 1987 liver transplantation was 
performed using ~uro-Col1ins solution for graft 
preservation, cyclosporine and prednisone (with 
or without supplemental azathioprine) for 
maintenance immunosuppression, andOKTI 
monoclonal antibody for treatment of steroid 
resistant rejection. During this petiod, 787 
302 Gordon RD, Fung J, Tzakis AG, et aI. Liver 
transplantation at the University of Pittsburgh, 1984 
to 1990. In: Clinical Transplants 1991. Teraski P, 
Cecka lM, eds. Los Angeles, UCLA Tissue Typing 
Laboratory, 1992; 105-17. 
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patients received a liver transplant with an actual 
12-month patient survival of 78.9% and first 
graft survival of 62.4%. Of ·the original 787 
patients, 214 (27.2%) patients ultimately 
required retransplantation of at least one more 
graft. 
The Pittsburgh team switched to UW 
solution for graft preservation starting in 
October, 1987 with a modest increase in patient 
and graft survival rates. Experimental trials with 
FK506 began in 1989, and from g~nuary 1989 
through December 1990, 822 patients received a 
liver transplant, including 399 who were treated 
primarily with FK506 instead of cyclosporine, 
and 103 patients who were switched from 
cyclosporine to FK506 as part of a graft rescue 
protocol. During this period, observed patient 
survival improved at one year to 83.1 % and one-
year graft survival improved to 73.5%. Only 
16.8% of these patients required a second graft. 
. . A breakdown of the indications for liver 
transplantation during the two periods of 
observation is shown in table 12. Postnecrotic 
cirrhosis, including chronic active hepatitis B, 
autoimmune hepatitis, and cryptogenic cirrhosis 
(which includes most patients with chronic 
active hepatitis C) remains the most common 
indication for liver transplantation. As in the 
nationwide experience, there has been a 
significant increase in the number of 
transplantations perform~d for alcoholic 
cirrhosis. 
Patient and graft survival rates for liver 
transplantation are shown in table 13. 
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Survival 
Significant improvement in survival rates are 
seen for patients with fulminant hepatic failure, 
biliary atresia, primary sclerosing cholangitis, 
and chronic active hepatitis B. Earlier referral of 
patients and aggressive protocols for 
preoperati ve management, including 
intracerebral blood flow monitoring and 
methods for prevention of excess intracranial 
pressure, may have contributed to the 
improvement seen in patients with fulminant 
hepatic failure. 
Earlier patient referral, more experience in 
performing transplantation in patients with 
previous biliary surgery; and restraint in the use 
of invasive surgical procedures may have 
contributed to the improvements seen for 
primary sclerosing cholangitis and biliary 
atresia. Technical' improvements in methods for 
arterial reconstruction and use of reduced liver 
grafts for small children may also be important 
factors in the improved results for biliary atresia . 
Exclusion of patients with hepatitis B early 
antigen (HBeAg) or high titers of HBV DNA 
from transplantation and routine use of 
t'mmunoprophylaxis with immune globulin after 
transplantation may explain the improved 
survival seen for patients with chronic active 
hepatitis B. Nonetheless, the long term 
progno~is for these patients remains guarded. 
Survival after transplantation for 
cryptogenic cirrhosis, which includes most 
patients with chronic active hepatitis C, remains 
favorable, but the true risks associated with 
hepatitis C can only be assessed as the newer 
Orthotopic Liver Transplantation 
techniques for characterizing this virus are 
applied to the liver transplant population. 
Preliminary evidence indicates that greater than 
90% of patients remain HeV positive after 
transplantation, but the implications for the 
subsequent development of cirrhosis in the graft 
are not yet clear.9o 
Overall, the results of liver transplantation 
for cancer have been disappointing. Some slow 
growing sarcomatous tumors, such as epitheloid 
hemangioendotheliomas, have a favorable 
prognosis with liver transplantation. 303 
Although most metastatic tumors are not 
suitable for liver transplantation, the 
neuroendocrine tumors are an exception.304, 305 
Efforts to improve the prognosis of patients 
with hepatocellular and biliary tract cancers 
must continue. At the present time, the best 
results are seen with patients with small « 3 
em), uni- or binodular tumors. Patients with 
large or multiple tumors have a high recurrence 
rate after transplantation.9o Some encouraging 
303 Makowka L, Tzakis AG, Mazzaferro V, et al. 
Transplantation of the liver for metastatic endocrine 
tumors of the intestine and pancreas. Surg Gynecol 
Obstet 168:107-11, 1989. 
304 Kelleher MB, Iwatsuki S, Sheahan DG. 
Epitheloid hemangioendothelioma of liver. 
Clinicalpathological correlation of 10 cases treated 
by liver transplantation. Am J Surg Pathol 13:999-
1008,1989. 
305 Alsina AE, BartusS, Hull D, Rosson R, 
Schwizer R. Liver transplantation for metastatic 




improvements in patient survival are being 
reported after preoperative intra-arterial 
chemotherapy for patients with advanced-stage 
hepatoma, but longer follow-up of more patients 
is needed.306 Given the current shortage of 
organs, liver transplantation for hepatobiliary 
cancers should probably be restricted to centers 
with well delineated protocols designed to test 
new approaches to this vexing problem. 
306 Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl 
TE. Prolonged survival after liver transplantation for 
advanced-stage hepatocellular carcinoma. 
Transplant Proc 25: 1128-9, 1993. 
Liver Transplantation 
Table 1. Indications for Liver 
Transplantation 
1. Advanced Chronic Liver Disease 
• Cholestatic Uver Disease 
Primary Biliary Cirrhosis (PBC) 
Primary p~lerosing Cholangitis (PSC) 
Secondary Biliary Cirrhosis 
Biliary Atresia 
Bile Duct Paucity Syndrome 
Familial Cholestatic Syndromes 
• Hepatocellular Disease 
Chronic Viral-induced Uver Disease 
Chronic Drug-Induced Liver Disease 
Alcoholic Uver Disease 
Chronic Autoimmune Uver Disease 
• Vascular Disease 
Budd-Chiari Syndrome 
Veno-occlusive Disease 
2. Hepatic Malignancies 
Hepatocellular Carcinoma (HCC) 
Cholangiocarcinoma 
Sarcomas of the liver 








Acute Alcoholic Hepatitis 














Table 1 (con't). Indications for Liver 
Transplantation 






Crigler-Naliar Syndrome Type II 
Erythropoietic Protoporphyria 
Urea-Cycle Deficiencies 
Glycogen-Storage Disease Type I & IV 




Protein C Deficiency 
Protein S Deficiency 
Antithrombin III Deficiency 
Type A and B Hemophilia 
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Thromboc 0 enia 
Leuco enia 



















Table 3. Clinical and Biochemical 
for Liver Transplantation 
1. Acute Liver Failure 
Bilirubin> 10-20 mgldl and increasing 
Prothrombin time> 10 sec. above normal and increasing 
Encephalopathy (Grade 3 and progressing) 
2. Chronic Liver disease 
• Cholestatic Uver Disease 
Bilirubin> 15 mgldl 
Intractable Pruritus 
Severe Bone Disease 
• Hepatocellular Uver Disease 
Albumin < 2.5 gldL 
Hepatic encephalopathy 
Prothrombin Time > 5 sec. above normal 
• Factors Common to Both Types of Uver Disease 
Hepato-renal syndrome 
Recurrent Spontaneous Bacterial Peritonitis 
Intractable Ascites 
Recurrent Variceal Bleeding 
Recurrent Episodes of Biliary Sepsis 




to Assess the Timing 
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Table 4 - Contraindications to Liver Transplantation 
Absolute 
Extra hepato-biliary sepsis 
Hepato-biliary malignancy with extra-hepatic 
metastases 
Severe cardio-pulmonary disease 
AIDS 
Relative 
Portal vein thrombosis 
HBV ESLD with active viral replication 
HIV positivity 
Marked obesity 
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Table 5 - Other organ systems and End-Stage Liver Disease 
I. THE HEART 
A) Atherosclerotic Heart Disease 
- older age> 50 years 
- familial hypercholesterolism 
- diabetes mellitus 
B) Cardiomyopathy 
- alcohol 
- Wilson's disease 
- hemochromatosis 
- glycogen storage disease 
C) Right Heart Function 
Autoimmune Hepatitis 
- pulmonary hypertension 
- pulmonary fibrosis 
cystic fibrosis 
alpha-1 antitrypsin deficiency 
II. THE LUNGS 
A) Obstructive Disease without Infection 
- a1 antitrypsin deficiency 
- IgA deficiency with bronchitis 
- cystic fibrosis 
B) Restrictive Disease 
-chronic autoimmune hepatitis 
C) Vascular Disease 
- chronic active hepatitis (HCV) 
- a1 antitrypsin deficiency 
- hypercoagulable status 
• Budd Chiari 
• polycythemia rubra vera 
• paroxysmal nocturnal hemoglobinuria 
• protein C or S deficiency 
• antithrombin III deficiency 
D) Hepatopulmonary Syndrome 
- pan lobular lung disease 
- focal lung disease 
III. RENAL FUNCTION 
A) Glomerulopathy 
- chronic hepatitis B. ? C 
B) IgA Nephropathy 
- alcoholism 
C) Interstitial nephritis 
- chronic autoimmune hepatitis 
- drug-induced liver disease 
D) Glomerulonephritis 
- chronic autoimmune hepatitis 
E) Renal Calculi 
- metabolic disease 
- PSC with IBD 
F) Hypertension/Atherosclerosis 
- older patients 
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Liver Transplantation Tables 
Table 6. Most common indications for liver replacement in the United States, 1988-1990 
1988 1989 1990 
Patients 1,489 1,861 2,308 
Fulminant failure 7.7% 7.2% 8.2% 
Hepatitis A 0.6% 0.5% 0.5% 
Hepatitis B 1.1% 2.0% 1.3% 
Hepatitis, non-A, non-B 3.0% 2.1% 3.5% 
Drugltoxin 1.3% 1.2% 1.0% 
Other or unspecified 1.6% 1.5% 2.7% 
Postnecrotic cirrhosis 40.8% 47.2% 51.5% 
Autoimmune hepatitis 4.0% 3.0% 3.5% 
Chronic active hepatitis B 5.8% 6.0% 6.2% 
Chronic active hepatitis, non-A, non-B 10.8% 12.5% 17.1% 
Cirrhosis, other or unspecified 11.0% 11.3% 11.1% 
Alcoholic cirrhosis 9.1% 15.1% 17.8% 
Cholestatic liver disease 36.4% 34.3% 27.8% 
Primary biliary cirrhosis 12.9% 9.1% 8.5% 
Primary sclerosing cholangitis 9.4% 9.4% 7.8% 
Secondary biliary cirrhosis 0.9% 0.8% 0.8% 
Biliary atresia 13.1% 11.4% 9.5% 
Other 0.1% 0.1% 0.2% 
Metabolic disorders 6.0% 5.3% 5.6% 
Alpha-i-antitrypsin deficiency 2.4% 2.6% 2.2% 
Wilson's disease 1.6% 0.9% 1.1% 
Hemochromatosis 0.6% 0.8% 1.2% 
Other 1.3% 1.0% 1.2% 
Benign neoplsms 0.7% 0.4% 0.3% 
Polycystic liver disease 0.5% 0.3% 0.2% 
Other 0.2% 0.1% 0.1% 
Malignant neoplasms 5.1% 5.7% 4.9% 
Hepatocellular carcinoma 3.1% 2.9% 2.7% 
Cholangiocarcinoma 0.7% 1.1% 0.6% 
Hemangio-endothelioma 0.1% 0.2% 0.3% 
Miscellaneous 16.4% 14.9% 12.2% 
Budd-Chiari 1.5% 1.0% 0.7% 
Congenital hepatiC fibrosis 0.4% 0.4% 0.4% 
Cystic fibrosis 0.5% 0.1% 0.3% 
Adapted from Belle et aI.299 
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Table 7. Patient survival rates in the United States after liver transplantation based on 
recipient age, 1988-1990 
6 month 1-year 3 years 
< 3 years 77% 75% 67% 
3-17 years 83% 81 % 75% 
18-29 years 79% 76% 65% 
30-39 years 84% 79% 72% 
40-49 years 82% 78% 67% 
50-59 years 77% 73% 63% 
~ 60 years 75% 71% 61% 
Adapted from Bell et al.299 There were 5,658 patients at risk at one month, 4,928 at 6 months, 3,978 
at 12 months, and 1,172 at 36 months. 
Table 8. Adult E~ 18 years) patient survival rates in the United States after liver 
transplantation, 1988-1990 
I 6 month 1-year 3 years 
I 
Fulminant hepatic failure 68% 65% 60% 
Chronic active hepatitis, non-A, non-B 80% 77% 68% 
Chronic active hepatitis B 77% 69% 54% 
Alcoholic cirrhosis 81% 79% 65% 
Primary biliary cirrhosis 86% 84% 78% 
Primary sclerosing cholangitis 88% 85% 79% 
Metabolic disorders 79% 74% 67% 
Malignant neoplasms 71% 60% 28% 
Adapted from Bell et al.299 
Table 9. Pediatric « 18 years) patient survival rates in the United States after liver 
transplantation, 1988-1990 
6 month 1-year 3 years 
Fulminant hepatic failure 65% 64% *62% 
Biliary atresia 82% 80% 75% 
Cholestatic cirrhosis 83% 83% 83% 
other cirrhosis 84% 77% 67% 
Metabolic disorders 88% 87% 75% 
Malignant neoplasms 69% 69% *41 % 
Adapted from Bell et al.299 
*Figures shown are 2-year survival rates since 3-year results were not available for these indications. 
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Table 10. Patient survival rates in the United States after liver transplantation stratified 
according to patient status at the time of surgery, 1988-1990 
6 month 1-year 3 years 
i 
Working full time/ attending school 85% 75% 75% 
Partially disabled/subnormal growth 85% 77% 75% 
Homebound/failing to thrive 86% 77% 72% 
Hospitalized 79% 70% 64% 
Intensive care 78% 69% 67% 
On life support 64% 57% 54% 
Adapted from Bell et al.299 
Table 11. Patient survival rates in the United States after liver transplantation stratified by 
donor-recipient ABO compatibility, 1988-1990 
ABO identical 
ABO mismatched, compatible 
ABO mismatched, incompatible 
Adapted from Bell et al.299 










Table 12. Most common indications for liver replacement at the University of Pittsburgh 












Primary liver cancer 
Adapted from Gordon et al.302 
I Jan 1984-Sep 1987 Jan 1989- Dec 1990 
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Liver Transplantation Tables 
Table 13. Observed 12-month patient and graft survival rates for common indications for 
liver transplantation at the University of Pittsburgh 
Jan 1984-Sep 1987 Jan 1989- Dec 1990 
Patient Graft Patient Graft 
Survival Survival Survival Survival 
Fulminant hepatic failure 61.1% 36.1% 79.2% 58.3% 
Postnecrotic cirrhosis 76.1% 65.3% 82.1% 73.9% 
Cryptogenic cirrhosis 78.9% 67.5% 81.4% 73.5% 
HBsAg+ cirrhosis 59.3% 51.9% 86.6% 81.1% 
Autoimmune CAH 82.4% 70.6% 84.0% 72.0% 
Alcoholic cirrhosis 76.9% 71.8% 82.6% 75.4% 
Biliary atresia 65.1% 50.7% 88.9% 77.8% 
Primay biliary cirrhosis 75.6% 65.9% 81.8% 69.7% 
Sclerosing cholangitis 83.6% 76.4% 98.2% 80.0% 
Genetic disorders 76.4% 75.0% 84.8% 81.8% 
Alpha-1-antitrypsin deficiency 80.0% 80.0% 77.8% 77.8% 
Wilson's disease 76.9% 69.2% 100,0% 80.0% 
Primary liver cancer 50.0% 50.0% 70.7% 63.8% 
Adapted from Gordon et al.302 All patients were followed for at least one year and there were no patients lost to 
follow-up. The survival rates are actual, observed survival rates, not actuarial estimates. 
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The phenomenon of cell migration (with repopulation and chimerism) which is 
postulated to be the basis of graft acceptance. Note the interaction at the site of donor-
recipient mutual cell engagement. This is thought to be the first step toward donor 
specific non-reactivity (tolerance) by a mechanism of peripheral clonal "silencing". 
Cadaveric organ donors in the United States, 1990-1992. 
Highway fatalities per 100 vehicular million miles traveled. 
Seatbelt usage by United States motor vehicle operators. 
Median waiting time of candidates for a liver transplant in the United States 
Death rate for patients waiting for liver transplantation in the United States. 
The pump driven veno-venous bypass is used to decompress the systemic and splanchnic 
venous beds during the anhepatic phase of the operation. Outflow lines to the pump are 
placed in the iliofemoral system via a cutdown on the saphenous vein and a return 
cannula is placed in the axillary vein. From Casavilla A, et al., with permission. 167 
The "piggyback" method of graft implantation. (A) The recipient vena cava is left intact 
and a clamp is applied across the Origin of the major hepatic veins. (B) 33A cuff is 
prepared by joining the origins of the middle and left hepatic veins. The right hepatic 
vein (not shown here) is usually tied off. (C) The suprahepatic vena cava of the graft is 
sewn to the funnel of the hepatic veins and the infrahepatic cava of the graft is Simply 
tied off. The liver rests on top of the recipient vena cava. From Casavilla A, et al., with 
permission. 167 
Steps in the implantation of an orthotopic liver graft. (A) Completion of the suprahepatic 
vena cava anastomosis. (B) Completion of the intrahepatic vena cava anastomosis. The 
portal vein is flushed with cold albumin or electrolyte solution to wash out the high 
potassium containing preservation fluid and to eliminate air in the vena cava. (C) The 
portal vein bypass cannula is removed and the portal vein anastomosis is completed. 
From Casavilla A, et at., with permission. 167 
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Use of a jump graft of donor iliac artery for extranatomic reconstruction of the hepatic 
arterial supply. The graft is passed through the transverse mesocolon, anterior to the 
pancreas, and posterior to the distal stomach to emerge at the hepatic hilum anterior and 
medial to the portal vein. Alternative sites for the origination of an arterial jump graft 
include the right iliac artery and the supraceliac aorta (not shown). From Casavilla A, et 
al., with permission. 167 
Use of a jump graft of donor iliac vein from the superior mesenteric vein to the donor 
portal vein. The graft is tunneled through the transverse mesocolon, anterior to the 
pancreas, and posterior to the stomach to reach the hepatic hilum. From Casavilla A, et 
al., with permission. 167 
'Ule biliary reconstruction. If the recipient duct is normal and closely matches the donor 
duct in caliber, an end-to-end reconstruction over a T-tube is performed using interrupted 
5-0 or 6-0 polyglycolic acid suture. In cases in which the anatomy is not favorable for a 
this technique, an eighteen inch Roux-en-Y limb of jejunum is created and an end-to-side 
choledochojejunostomy over an internal silastic stent is performed using running 5-0 or 
6-0 polyglycolic acid suture (inset). From Casavilla A, et al., with permission. 167 
Liver transplantations per year in the United States, 1983-1992. 
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H V G (Rejection) 
The phenomenon of cell migration (with repopulation and chimerism) 
which is postulated to be the basis of graft acceptance. Note the 
interaction at the site of donor-recipient mutual cell engagement. This 
is thought to be the first step toward donor specific non-reactivity 
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Source: National Highway Traffic Safety Administration 
Figure 4. Seatbelt usage by United States motor vehicle operators. 
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bile duct o 
Figure 7. 
7 mm Gott tubing 
or 16 Fr chest 
tube 
The pump driven veno-venous bypass is used to decompress the 
systemic and splanchnic venous beds during the anhepatic phase 
of the operation. Outflow lines to the pump are placed in the 
iliofemoral system via a cutdown on the saphenous vein and a 
return cannula is placed in the axillary vein. 
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~~ __ ~~_ Donor infrahepatlc 
~""""D:::: Inferior vena cava 
The "piggyback" method of graft implantation. (A) The recipient 
vena cava is left intact and a clamp is applied across the origin of 
the major hepatic veins. (8) A cuff is prepared by joining the 
origins of the middle and left hepatic veins. The right hepatic vein 
(not shown here) is usually tied off. (C) The suprahepatic vena 
cava of the graft is sewn to the funnel of the hepatic veins and the 
infrahepatic cava of the graft is simply tied off. The liver rests on 










:;;tr--- Portal vein 
anastomosis 
Steps in the implantation of an orthotopic liver graft. (A) Completion of the 
suprahepatic vena cava anastomosis. (8) Completion of the infrahepatic 
vena cava anastomosis. The portal vein is flushed with cold albumin or 
electrolyte solution to wash out the high potassium containing preservation 
fluid and to eliminate air in the vena cava. (C) The portal vein bypass can-









Figure 1 O. Use of a jump graft of donor iliac artery for extranatomic recon-
struction of the hepatic arterial supply. The graft is passed 
through the transverse mesocolon, anterior to the pancreas, 
and posterior to the distal stomach to emerge at the hepatic 
hilum anterior and medial to the portal vein. Alternative sites 
for the origination of an arterial jump graft include the right iliac 
artery and the supraceliac aorta (not shown). 
Figure 11. Use of a jump graft of donor iliac vein from the superior mesenteric 
vein to the donor portal vein. The graft is tunneled through the trans-
verse mesocolon, anterior to the pancreas, and posterior to the stom-







Figure 12. The biliary reconstruction. If the recipient duct is normal and closely 
matches the donor duct in caliber, an end-to-end reconstruction over 
aT-tube is performed using interrupted 5-0 or 6-0 polyglycolic acid 
suture. In cases in which the anatomy is not favorable for a this 
technique, an eighteen inch Roux-en-Y limb of jejunum is created 
and an end-to-side choledochojejunostomy over an internal silastic 
stent is performed using running 5-0 or 6-0 polyglycolic acid suture 
(inset) 
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Figure 13. Liver transplantations per year in the United States, 1983-1992. 
